

CURRICULUM VITAE

Kenneth Dale Burman, M.D.

Office: 110 Irving Street NW, Suite 2A-72
Washington, DC 20010
(202) 877-6563
Kenneth.D.Burman@MedStar.net

Wife's Name Mary Eileen (Molly)
Children's Names Edward Matthew
Stephen Joseph
Andrew Clarkson
David Alexander
Emily Scott

Education:

Washington University (St. Louis) A.B., 1966
University of Missouri Medical School, M.D., 1970
Barnes Hospital Internship 1970-1971, Internal Medicine
Barnes Hospital Residency 1971-1972, Internal Medicine
Walter Reed Army Medical Center Fellowship Endocrinology 1972-1974

Professional Societies:

American Federation for Clinical Research, 1973
Member, American College of Physicians, 1974
Missouri Certification Examination, 1970
Licensure: Missouri, Washington, D.C., Maryland
Attending Physician, DC General Hospital, Howard University Service, 1975
American Medical Association, 1972
American Thyroid Association, 1975
Member, Endocrine Society, 1976
Fellow, American College of Physicians (FACP), April 1979
American Association of the Advancement of Science, 1982
American College of Nutrition, 1983
Institute of Nutrition, 1984
American Society for Clinical Nutrition, 1984
American Association Immunologist, 1985
Society of Medical Consultants to the Armed Forces, 1991
Academy of Medicine, 1993
American Association of Clinical Endocrinologists, 2000
Menopause Society, 2003
National Lipid Association, 2010
Alliance for Academic Medicine (AAIM) 2013
Association of program Directors in Endocrinology and Metabolism (APDEM) 2006

Board Certification:

National Medical Boards Parts I, II, III, Certified, 1971
American Boards of Internal Medicine, June 1973
Board Certification, Endocrinology and Metabolism, October, 1975
American Board of Nutrition - Certified as a Specialist in Clinical Nutrition, 1984

Academic Appointments:

Professor of Medicine, Georgetown University, Washington, DC
Professor of Medicine, Uniformed Services University of the Health Sciences,
Bethesda, MD
Clinical Professor, Department of Medicine and Surgery (Otolaryngology), Georgetown
University School of Medicine, Washington, DC
Clinical Professor, Department of Medicine, George Washington University School of
Medicine, Washington, DC
Assistant Chief, Endocrine Service, Walter Reed Army Medical Center, Washington, DC (1978 -
1991)
Assistant Commandant for Students, Uniformed Services University of the Health Sciences,
Bethesda, MD (1980-1984).
Consultant to the Surgeon General of the US Army in Nutrition (1985-1991)
Consultant in Endocrinology to the Attending Physician's Office, The Capitol,
Washington, DC (1985-1994)
Chief, Endocrinology, Uniformed Services University of the Health Sciences, Bethesda, MD
(1991 - 1994)
Director, Endocrine Training Program, Walter Reed Army Medical Center, Washington, DC
(1991-1994).
Director, Section of Endocrinology, MedStar Washington Hospital Center, Washington, DC
(1994 - Present)
Director, Integrated Endocrine Training Program, MedStar Georgetown University Hospital/
MedStar Washington Hospital Center, Washington, DC (2002-present).
Regional Director, Endocrine, Medstar, Washington, DC (2016-present)

Honors and Awards:

1976 Fellow, American College of Physicians

1982 Peter Forsham Award, given to the individual in government service who is performing outstanding research

1984 Van Meter U.S.V. Award, given by the American Thyroid Association for outstanding contributions to our understanding of thyroid disease

1985 American Federation for Clinical Research, Eastern Section Young Investigator Award, 1985, for outstanding contributions in research concerning the causes of thyroid disease

1986 Alpha Omega Alpha

1986 American Society of Clinical Investigation

1987 The Claire Chennault Award given to an Outstanding Teacher, Walter Reed Army

Medical Center

- 1989 Distinguished Physician Award given to graduate of University of Missouri Medical School who has contributed significantly to medical research and patient care
- 1997 Laureate, American College of Physicians
- 1997 Vicennial Medal, Georgetown University, for teaching and patient care
- 1998 Member, American Thyroid Association Council
- 2001 Distinguished Alumni Award, University of Missouri.
- 2004 Awarded Mastership in the American College of Physicians
- 2007 Barbara and William James Howard Award for Academic Excellence, Washington Hospital Center
- 2007 Paul Starr Award for Career Excellence in Clinical Research, American Thyroid Association
- 2007 Board, American Thyroid Association (2007-2010),
- 2008 President, American Thyroid Association (2008-2009).
- 2010 Deputy Editor, Journal of Clinical Endocrinology and Metabolism (2010-2015).
- 2010 Overholser Award Lecture, Physician Alumni Organization, University of Missouri Medical School.
- 2011 Dr. John Dunn Lecture, University of Virginia Medical Center, Charlottesville, VA.
- 2011 Dr. Leon P Georges Lecture, Eastern Virginia Medical Center, Norfolk, VA.
- 2013 Dr. Walter Lester Henry Award for Lifetime Excellence in Teaching, American College of Physicians, DC Chapter.
- 2014 Golden Cane Award for Clinical Expertise, Medstar Washington Hospital Center
- 2016 John Stanbury Thyroid Pathophysiology Medal which recognizes outstanding research contributions, either conceptual or technical, to the understanding of thyroid physiology or the pathophysiology of thyroid disease, as evidenced by having a major impact on research or clinical practice related to thyroid diseases.
- 2017 Citation of Merit, University of Missouri Medical School; awarded to an outstanding graduate.

Selected Committees:

- | | |
|-----------------------|------------------------------|
| 1981 - Present | Reviewer for VA Grants |
| 1982 - Present Ad Hoc | Reviewer for NIH Grants |
| 1985 Present Ad Hoc | Reviewer for Canadian Grants |

1982	Ad Hoc	Endocrine Society Representative to National Academy of Science Committee on Health Manpower Needs
1983		American Thyroid Association - Constitutional Ad Hoc Committee on revising the by-laws
1983 - 1990		Endocrine Society - Future meetings committee
1983		Reviewer for National Science Foundation Grants
1984		Ad Hoc Reviewer for Heritage Scientific Foundation, Alberta, Canada
1984 - 1986		Chairman, Society of Uniformed Endocrinologists
1986		- 1991 Chairman, Future Meetings Committee, Endocrine Society
1987		Finance Committee, American Thyroid Association
1987		Co-Chairman, Local hosts, American Thyroid Association
1987		Coordinator, Clinical Nutrition Course, USUHS
1988		Ad Hoc Review, grants, American Diabetes Association
1988		Program Committee, American Society of Clinical Nutrition
1988		Awards Committee, American Thyroid Association
1988		Cholesterol Advisory Group to the Surgeon General
1988		- 2000 Abstract reviewer, Endocrine Society, American Thyroid Association
1989		Chairperson, By-Laws Committee, American Thyroid Association
1989		Program committee, American Thyroid Association
1990		Reviewer for Veterans Administration Merit Review and for Allegheny- Singer Foundation
1990		Chair, Subcommittee on International Meetings, Endocrine Society
1991		Organizer, American Thyroid Association Symposium, Bethesda, MD
1992		Member, Education Committee, American Thyroid Association
1993		Search Committee for Radiology Chairperson, USUHS, Bethesda, MD
1993 - 1994		Co-chair, Human Use Committee, Department of Clinical Investigation, Walter Reed
1999		Clinical Initiatives Committee, Endocrine Society
1999- 2002		Scientific Advisory Board, Novavax, Inc.
2001		Local Organizer, American Thyroid Association Meeting
2001		Chair, Public Health Committee, American Thyroid Association
2002		Advisory Board, Thyroid Cancer Support Group
2002		Advisory Board, Thyroid Foundation of America
2003-present		Scientific Review Board, General Clinical Research Center, Georgetown University Medical Center; CTSA Grant Scientific Review Board
2007-2015		FDA Advisory Committee (Endocrine and Metabolism)
2008-2010	Chair, FDA Advisory Committee (Endocrine and Metabolism); ad hoc member 2011 -	
2008		Consultant to the Endocrine Society's Hormone Foundation website
2007-2010		Board of Directors, American Thyroid Association
2008-2009		President, American Thyroid Association
2009		Consultant to Medical Letter
2007-2010		Endocrine Society, Laureate Award Committee
2011		Professor Evaluation Committee, Harvard University
2010		American Thyroid Association Anaplastic Thyroid Cancer Guideline Committee
2011		American Thyroid Association Levothyroxine Replacement Committee
2000-2011		Thyroid Cancer Support Group (ThyCa) Consultant

2008-2011	Endocrine Fellows Foundation Grant Reviewer
2011	Endocrine Society Poster Judge
2010-	American College of Physicians MKSAP Committee
2010-	Medscape, Consultant
2005-	UpToDate, Consultant, Author
2011-	Academic Promotions Committee, Georgetown University
2010-	Glycemic Control Committee, MedStar Washington Hospital Center
2011-	Council, Association of Specialty Professors (ASP) (AAIM)
2012-	Chair, Spring Thyroid Hormone Symposium, American Thyroid Association
2009-2012	American Thyroid Association Anaplastic Thyroid Cancer Guideline Committee
2013	American Thyroid Association, Finance Committee
2013	International Thyroid Oncology Group (ITOG), Finance and Ethics Committee (Ad Hoc)
2013	Lombardi Comprehensive Cancer Center, Clinical Research Committee, Georgetown University
2015	Chair, Finance Committee, American Thyroid Association
2015	Development Committee, American Thyroid Association
2015	LEAD Program Mentor, Medstar
2017	FDA Endocrine Advisory Committee

Selected Invited Lectures:

1976	Symposium on Anorexia Nervosa, NIH, Bethesda, MD
1977	University of Missouri Medical Center, Columbia, MO
1981	Massachusetts General Hospital, Boston, MA
1981	Guthrie Clinic, Sayre, PA
1980, 1982	Endocrine Society Course in Radio Ligand Techniques, Bethesda, MD
1980	Conference on Thyroid Hormones, Tucson, AZ
1981	Medical Grand Rounds, National Naval Medical Center, Bethesda, MD
1982	International Workshop on Hormone Assays and Standard, NIH, Bethesda, MD
1982	Medical Grand Rounds, George Washington Medical Center, Georgetown University and NIH, Bethesda
1983	Visiting Professor in Endocrinology, Fitzsimmons Army Medical Center, Aurora, CO
1983	Geisinger Clinic, Danville, PA
1983	American Thyroid Association Annual Meeting, Sept. 1983
1983	Wayne State University Thyroid Symposium, Detroit, MI
1984	Van Meter Address, American Thyroid Association, New York, NY
1984	American College of Physicians Regional Meeting, San Francisco, CA
1984	Guthrie Clinic, Sayre, PA
1984	Beth Israel Hospital, Boston, MA
1985, 1987, 1998	Johns Hopkins Medical Center, Baltimore, MD
1985	Young Investigators Award Address, American Federation of Clinical Research, Baltimore, MD
1986	Medical College of Virginia
1992	Graves' Ophthalmopathy Symposium, Washington Hospital Center,

Washington, DC

1988 Visiting Professor, Dalhousie University, Halifax, Nova Scotia, Canada

1991 Visiting Professor, Montreal General Hospital, McGill University, Montreal, Quebec, Canada

1991 Medical Grand Rounds: George Washington University Medical Center, Washington, DC

1991 Visiting Professors, Samuel Haines, Lectureship, Mayo Clinic, Rochester, MN

1991 Invited Speaker, Autoimmune Thyroid Symposium, Montreal, Canada

1992 Invited Speaker, The Royal College of Physicians and Surgeons of Canada, Canadian Society for Endocrinology and Metabolism, Annual Meeting, Ottawa, Canada

1992 Invited Speaker, Northern Virginia Institute for Continuing Medical Education Conference

1993 Immunology Council, Johns Hopkins University Medical Center, Baltimore, MD

1993 University of Michigan Medical Center, Ann Arbor, MI

1993 Geisinger Clinic, Danville, PA

1993 - 2010 NIH Endocrine Board Review Course

1997 - 2003 Endocrine Society Board Review Course

1994 Thyroid Workshop, Portsmouth, VA

1995 Thyroid Workshop, Boston, MA

1996 Endocrine Course, Charlotte, NC

1997 Endocrine Course, Charleston, SC

1998 Endocrine Course, Milwaukee, WI

1999 North Atlantic Endocrine Society, Bar Harbor, ME

1999 Beth Israel Medical Center, New York, NY

1999 Abington Memorial Hospital, Philadelphia, PA

2000 University of Maryland, Bethesda, MD

2000 Georgetown University, Washington, DC

2001 Beebe Medical Center, Dewey DE

2001 Princeton Medical Center, Princeton, NJ

2001 University of Virginia, Charlottesville, VA

2001 Walter Reed Army Medical Center, Washington, DC

2003 East Carolina University, Greenville, NC

2003 Brown University, Providence, RI

2003 Moses Nussbaum Lectureship, Beth Israel Hospital, NY, NY

2003 Abbott Lecture, Sinai Hospital, Baltimore, MD

2004 American Thyroid Association, Vancouver Canada

2005 American Association of Clinical Endocrinologist, Washington, DC

2005 Ohio State University, Columbus, OH

2005 Marshall University, Huntington, WV

2005 Dartmouth University, Hanover, NH

2006-present American College of Physicians Board Review

2006 Lankenau Hospital, Philadelphia, PA

2007 Walter Reed Army Medical Center, Washington, DC

2007 Lankenau Hospital, Philadelphia, PA

2007 Paul Starr Award Plenary Lecture, American Thyroid Association Meeting, New York City.

2002-present NIH Board Review Course, Bethesda, MD

2008 Endocrine Society, Clinical Endocrine Update, Boston, MA
2009 University of Miami, Florida
2009 European Thyroid Association, Lisbon, Portugal
2010 University of Louisville, Louisville, KY
2006-present American College of Physicians Board Review
2010 J.S.L.Browne Lecture, McGill University, Montreal, CA
2010 Christiana Hospital, Wilmington, DE
2010 Sinai Hospital, Baltimore, MD
2010 Endocrine Society, San Diego, CA
2010 Mid-Atlantic Meeting, American Association of Clinical Endocrinologists, Rockville, MD
2010 Plenary Lecture, American College of Physicians (Military Section), Bethesda, MD
2010 International Thyroid Meeting, Paris, France
2011 University of Maryland Medical Center, Baltimore, MD
2011 University of Virginia Medical Center, John Dunn Visiting Professor, Charlottesville, VA
2011 Eastern Virginia Medical Center, Leon P. Georges Visiting Professor, Norfolk, VA
2011 New York Thyroid Club, Manhattan, NY
2011 Case Management Forum, Endocrine Society Annual Meeting, Boston, MA
2011-present Frontiers in Reproductive Endocrinology, Washington, DC
2012 American College of Physicians Certification Course and Re-Certification Course, (2006-2012)
2012 Midatlantic Meeting, Society of Nuclear Medicine, Washington, DC 2013
Visiting Professor, University of Connecticut, Farmington, CT.
2013 Meet The Professor Session, T3, T4, or Both? Endocrine Society, San Francisco, CA, June, 2013
2013 Chair, Assessment of Recurrent/Persistent Cervical Node Thyroid Cancer, World Thyroid Cancer Congress, Toronto, CA.
2013 Chair, Symposium on Graves' Disease, American Thyroid Association Annual Meeting, San Juan, Puerto Rico
2013 St. Agnes Hospital, Baltimore, MD
2014 Visiting Professor, Department of Medicine, Yale University, New Haven, CT
2014 Visiting Professor, Boston University, Boston, MA
2015 Visiting Professor, Lankenau Medical Center, Philadelphia, PA 2015
Medical Grand Rounds, Howard University, Washington, DC
2015 Lecture on "Recurrent cervical papillary thyroid cancer" at the International Thyroid Congress, Orlando, FL.
2015 Thyroid Nodules, Howard University, Washington, DC
2016 Thyroid Nodules and Thyroid Cancer, Medstar Harbor Hospital
2016 Hypothyroidism and Thyroiditis, NIH/FAES Board Review Course
2017 Recurrent Thyroid Cancer, World Cancer Thyroid Congress, Boston, MA
2018, 2019 ACP Board Review, Washington, DC
2019 Frontiers Reproductive Endocrine Board Review, Washington, DC

Reviewer:

American Journal of Physiology
Annals of Internal Medicine

Achieves of Internal Medicine
Autoimmunity
Endocrine Related Cancer
Endocrinology
Immunology & Immunopathology
International Journal of Obesity
Journal of the American Medical Association
Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Investigation
Journal of Clinical Pharmacology
Journal laboratory and Clinical Medicine
Mayo Clinic Proceedings
Metabolism
Thyroid
American Journal of Physiology
Clinical Endocrinology
Cancer Control: Journal of the Moffitt Cancer Center.
Endocrine Related Cancer
Journal of Clinical Oncology
New England Journal of Medicine
Endocrine Related Cancers
Endocrine Practice

Editorial Board:

Journal of Clinical Endocrinology and Metabolism, January 1980 - December 1984;
January 00-04
Deputy Editor, Journal of Clinical Endocrinology and Metabolism 2010-2015
Thyroid, 1991 - Present
Endocrinology and Metabolism, 1995 – 1999
Reviews in Endocrine and Metabolic Disorders, 2006

Selected Community Activities:

Commissioner, Montgomery County Soccer League
Antiquarian Book Fair, Concord Hill School, Bethesda, MD
Advisory Committee, Stone Ridge School, Bethesda, MD
Landon School, Bethesda, MD - Health Committee, Education Committee, Computer Committee, Board of Trustees

Abstracts:

1. Burman KD, Klachko D, Senhauser DD, Burns TW, Sharp CG. Hashimoto's Thyroiditis Associated with an Unusual Pattern of Thyroid Autoantibodies. Clinical Research XVIII, p. 256, 1970.
2. Burman KD, Fox JD, Earll JM, Wartofsky L. Sources of Increasing Serum T3 in Newborn Sheep. American Thyroid Association, Inc. 50th Meeting, September 1974. Endocrinology (Suppl) 93: T-21, 1974.

3. Burman KD, Yeager H, Briggs B, Wartofsky L. Resin Hemoperfusion: A Potential New Treatment for Thyroid Storm, The Seventh International Thyroid Association Meeting, Abstract 93, June 1975, Boston, MA.
4. McGuire RA, Burman KD, Wartofsky L, Berman M. Compartmental Models for Maternal, Fetal, and Amniotic Fluid Transfer of Iodine, Triiodothyronine and Thyroxine in the Pregnant Sheep. Endocrine Society Meeting, Abstract 142, June 1975.
5. Burman KD, Read J, Wright FD, Earll JM, Wartofsky L. Thyroid Function in Amniotic Fluid. American College of OB-GYN Meeting, May 1976.
6. Burman KD, Dimond RC, Earll JM, Wartofsky L. Sensitivity to Lithium in treated Graves' Disease. Presented at American College of Physicians Meeting, April 1976.
7. Boehm TM, Burman KD, Wartofsky L. Synergistic Effects of Lithium and Iodine in the Treatment of Hyperthyroidism. Endocrine Society Meeting, 618, June 1976.
8. Burman KD, Dimond RC, McGuire RA, Earll JM, Strum D, Wartofsky L. The Effect of Varying Serum T4 Concentrations on Extra thyroidal Production of T3, Reverse T3, and 3-3' Diiodothyronine. *Clinical Research* 24:270, 1976.
9. Burman KD, Strum D, Dimond RC, Djuh YY, Earll JM, Wartofsky L. A Radioimmunoassay for 3,3' T2. Program 52nd Annual Meeting, American Thyroid Association Toronto. *Endocrinology* 98:7-17, 1976.
10. Smallridge RC, Wartofsky L, Desjardins RE, Burman KD. Reverse T3 Production Rates in Thyrotoxic, Euthyroid and Hypothyroid Subjects. *Clinical Research* 25: 302A, 1977.
11. Becker RA, Wilmore DW, Johnson DW, Burman KD, Wartofsky L. Alterations in Peripheral Thyroid Economy and Pituitary Responsiveness in Thermally Injured Man. *Clinical Research* 26:14A, 1978.
12. Becker RA, Johnson BW, Wilmore DW, Burman KD, Wartofsky L, Woeber KA. Alteration in Serum T3 and Reverse T3 in Thermal Injury. *Clinical Research* 24:270A, 1976.
13. Georges LP, Burman KD, Czerwinski C, Sode J, Wartofsky L. The Effect of Sedation and Awakening on Peripheral Thyroid Hormone Levels in the Subhuman Primate. *Clinical Research* 25:13A, 1977.
14. Wannemacher RW, Dinterman RE, Burman KD, Wartofsky L. The Possible Role of Thyroid Hormone in Regulating the Rates of Protein Degradation in Skeletal Muscle. *Federation Proceedings* 37:1315, 1978.
15. Wray HL, Burman KD, Smallridge RC, Alford JP, Wartofsky L. Effects of T3 and Reverse T3 Administration on Serum Tri-, Di-, and Monoiodothyronines in Sheep. *Federation Proceedings* 37:519, 1978
16. Smallridge RC, Wartofsky L, Dimond RC, Burman KD. 3', 5'-diiodothyronine and 3'monoiodothyronine: Development of Radioimmunoassays and Demonstration of in Vivo Peripheral conversion. Annual Endocrine Society Meeting, June 1978, Abstract 102.

17. Glass AR, Mellitt R, Burman KD, Swerdoff RS, Wartofsky L, Fisher DA. Effect of Dietary Composition on Serum T4 and T3 in Rats. *Clinical Research* 26:283A, 1978.
18. Wray HL, Burman KD, Alford JP, Wartofsky L. Effect of T3 and rT3 Administration on Plasma CAMP and GMP in Sheep. *Clinical Research* 26:16A, 1978.
19. O'Brian JT, Bybee D, Wartofsky L, Georges LP, Burman KD. Altered Peripheral Thyroid Hormone Metabolism and Diminished Hypothalamic Pituitary Responsiveness with Changes in Dietary Composition. *Clinical Research* 26:310A, April 1978.
20. Latham KR and Burman KD. Physiologic and Chromatographic Evidence for Separate T3 and T4 Receptors. American Thyroid Association, September 1978.
21. Smallridge RC, Ward K, Wartofsky L, Burman KD. 3',5'T2 to 3'T1 Conversion in Rat Liver and Solubilization of Multiple Phenolic Ring Deiodinases. American Thyroid Association, September 1978.
22. Bybee D, Taub M, Burman KD, Wartofsky L, Georges LP, O'Brian JT. The Effect of Hypocaloric Carbohydrate Feeding on Central and Peripheral Thyroid Hormone Regulation. *Clinical Research* 26:611, 1978.
23. Burman KD, Djuh YY, Kesler P, Wartofsky L. The Effect of T4 Administration on Hepatic Conversion of T4 to T3 in States of altered Carbohydrate Economy. Annual meeting of Endocrine Society, Miami, Florida, Abstract 327, June 1978.
24. Zwillich C, Martin B, Rose E, Charles A, Hofeldt F, Burman KD. The Effects of Dense Beta Sympathetic Blockade on Metabolic Rate and Thyroid Function in Normal Man. *Clinical Research* 27:263A, 1979.
25. Wannemacher RW, Dinterman RE, Burman KD, Wartofsky L. Thyroid Hormone: A Regulator of Protein Degradation in Skeletal Muscle. 11th International Congress of Biochemistry, Toronto, Canada, 8-13, July 1979.
26. Burman KD, Smallridge RC, Jones L, Ramos EA, O'Brian JT, Wright FD, Wartofsky L. Glucagon Kinetics in Fasting: A Metabolic Event Associated with Physiologic Alterations in Serum T3. *Clinical Research* 27:284A, 1979.
27. Burman KD, Smallridge RC, Osbune R, Dimond RC, Whorton NE, Kesler P, Wartofsky L. Nature of Suppressed TSH Secretion During Undernutrition: Effect of Fasting and Refeeding on TSH Responses to TRH infusion. *Clinical Research* 27:248, 1979.
28. Smallridge RC, Latham KR, Ward KE, Wartofsky L, Burman KD. Conditions Affecting 3', 5'diiodothyronine (3', 5'T2) to 3'-monoiodothyronine (3'T1) Conversion: Evidence for an Enzyme Separate from Thyroxine (T4) and Reverse T3 (rT3) 5'-deiodinase. *Clinical Research* 27:260A, 1979.
29. Latham KR, Smallridge RC, Tseng YL, Burman KD, Wartofsky L. Nuclear Thyroid Hormone Receptors in Heart and Liver: Long-term Effect of Hypo and Hyperthyroidism. *Clinical Research* 27:255A, 1979.

30. Pangaro L, Smallridge RC, Cahnmann HJ, Wright FD, Burman KD. Development of a Radioimmunoassay for $3,5T_2$ and demonstration of Conversion from T_3 . Endocrine Society Poster Session, Los Angeles, California, June 1979.
31. Burman KD, Latham KR, Djuh YY, Smallridge RC, Tseng YC, Lukes YG, Maunder R, Wartofsky L. Solubilized Nuclear T_3 and T_4 Receptors in Circulating Human Mononuclear Cells: Evidence for Increased Maximum Binding Capacities in Fasted Obese Subjects. Presented at the Endocrine Society, Los Angeles, California, June 1979.
32. Osburne RC, Bybee DE, O'Brian JT, Burman KD, Wartofsky L, Georges LP, Sensitivity of the Hypothalamic pituitary Axis to Triiodothyroxine in the Underfed State. Clinical Research, January 1980.
33. Smallridge RC, Smith CE, Wright FD, Wartofsky L, Burman KD. Metabolic Clearance and Production Rates of $3,5T_2$ in Hyper- and Hypothyroidism. Comparison of Infusion Using labeled Versus Unlabeled Hormone. 61st Annual Meeting of the Endocrine Society Anaheim, California, Abstract 74, 13-15, June 1979.
34. Burman KD and Wartofsky L. The Effect of Dexamethasone, and Diet in Hepatic T_3 Murine Receptors. Thyroid Foundation Seminar, Tucson, Arizona, October 1980.
35. Burman KD, Djuh YY, Latham KR, Wartofsky L. White Cell T_3 Receptors Decrease in Critical Illness. Clinical Day, Annual Thyroid Association Meeting, San Diego, California, 5 November 1980.
36. Bongionvanni R, Burman KD, Boehm T. Measurement of Iodothyronines by HPLC. Annual Thyroid Association Meeting, San Diego, California, November 1980.
37. Chernow B, Burman KD, Johnson DL, O'Brian JT, Wartofsky L, Georges LP. Iodothyronines Bi-directional Transfer Across the Blood Brain Barrier. Clinical Meeting, San Diego, California, 5 November 1980.
38. Hay ID, Jiang NS, Burman KD, Gorman CA. Inner Versus Outer Ring Monodeiodination of Orally Administered D- or L-thyroxine in man. Clinical research, May 1981.
39. Rajagopal KR, Derderian SS, Jabbari B, Burman KD, Hunt KK. Obstructive Sleep Apnea in Hypothyroidism. American Thoracic Society, 1981.
40. Borst GC, Premachandra BN, Osburne RC, Burman KD, Johnsonbaugh RF. Euthyroid Familial Hyperthyroxenemia Due to an Abnormal Thyroid Hormone-Binding Protein. Endocrine Society, 1981.
41. Fear W, Burman KD, Wartofsky L, Latham KR. Acetylase Activity in Rat Liver Nuclei in Euthyroid, Hyperthyroid and Hypothyroidism. American Thyroid Association, September 1981.
42. Pangaro L, Little J, Gerris B, Burman KD. Modulation of Plasma Membrane Thyroid Hormone Receptors. American Thyroid Association, September 1981.
43. Glass AR, Smallridge RC, Vigersky R, Burman KD. High Serum T_3 in Nephrotic Syndrome: A Reflection of Increased T_4 Availability? Clinical Research 1982.

44. Smallridge RC, Whorten NE, Burman KD, Ferguson EW. Effect of Physical Conditioning and Acute Exercise on Serum T₄, rT₃, TSH and PRL Responses to TRH in Man. Endocrine Society, June 1982.
45. Borst GC, Burman KD, Osburne RC, Georges LP, O'Brian JT. Effect of Fasting in TRH Responsiveness in Hypothyroidism. Military Society of Endocrinology. San Francisco, June 1982 and American Thyroid Association Meeting, Quebec, Canada, September 1982.
46. Burman KD, Wartofsky L, Smallridge RC. Iodate Restores the Fasting Induced Decrement in TSH Secretion. European Thyroid Association, Brussels, Belgium, September 1982.
47. Wartofsky L, DeRuyter H, Smallridge RC, Burman KD. Thyrotropin Secretion in Starved Rats is Enhanced by Somatostatin Antiserum. European Thyroid Association, Brussels, Belgium, September 1982.
48. Chernow B, Zaloga G, Burman KD, Quinn A, Rainey T, Zajtchuk R. Chariopulmonary Bypass Surgery Rapidly Alter Thyroid Function. Clinical Research 31:257, 1983.
49. Chernow B, Zaloga G, Burman KD, chin R, Zajtchuk R. Diagnostic Dosages of TRH Raise Blood Pressure by a Noncatecholamine Mechanism. Clinical Research 31:257, 1983.
50. Glass AR, Vigersky RA, Burman KD. Divergent Effects of Nephrotic Syndrome on Metabolic Clearance Rate of T₄ and T₃ in Rats. Clinical Research 31:470, 1983.
51. Michenfelder J, O'Brian JT, Burman KD, Georges LP. The Influence of Thyroid Hormone in the Excretion of Catecholamines and their Metabolites during Semi-Starvation. Annual Air Force Physicians Meeting, San Antonio, TX, March 1983.
52. O'Brian JT, Michenfelder J, Burman KD. The Effect of Cold Climate upon T₄, T₄ and TSH Responses to TRH. Annual Air Force Physicians Meeting. San Antonio, TX, March 1983.
53. Baker J, Lukes YG, Smallridge RC, Burger M, Burman KD. A Sensitive and Rapid Enzymelinked Ammuo-sorbent Assay (ELISA) for Thyroid Stimulating Hormone Receptor Antibodies. Clinical Research 269, 1983.
54. Chernow B, Zaloga GP, Burman KD, Chin R, Zajtchuk R, Rainey TG, Lake CR. Diagnostic Dosages of TRH Raise Blood Pressure by a Non-catecholamine Mechanism. Society of Critical Care Medicine Annual Meeting, New Orleans, LA, June 1983.
55. Burman KD, Djuh YY, Ferguson RW, Wartofsky L, Latham KR. Beta Receptors in Peripheral Mononuclear Cells Increase Acutely during Exercise. Endocrine Society, San Antonio, TX, Abstract 472, June 1983.
56. Baker JR, Lukes YG, Burman KD. Class of Antibodies Binding the Thyroid Stimulating Hormone Receptor in Active Graves' Disease. Submitted to the American Thyroid Association presentation, Abstract 3, Sept. 1983,
57. Burman KD, Djuh YY, Baker JR. Circulating Beta Ligand Antibodies in Auto-immune Thyroid Disease. American Thyroid Association Annual Meeting, poster, Abstract 65, Sept. 1983.

58. Reed HL, Burman KD, George P, O'Brian JT. Thyroid Economy in cold Adaptation of Euthyroid Volunteers. *Endocrinology* 112:A1150, 1983.
59. Reed HL, Burman KD, Shakir KMM, O'Brian JT. Reduced Effect of Oral T3 on TSH Response to TRH after Antarctica Cold Exposure. *Clinical Research* 32:689, 1984.
60. Raines KB, Baker Jr.JR, Lukes YG, Burman KD. Functional Characterizations of AntiThyrotropin Antibodies in the Sera of Graves' Patients. American College of Physicians Annual Meeting, Atlanta, GA, April 1984.
61. Baker Jr JR, Lukes YG, Burman KD. Production, Isolation and Characterization of Antiidiotypic Antibodies Directed against Human Anti-TSH Receptor Antibodies. *Clinical Research*, May 1984.
62. Chernow B, Snyder R, Zaloga GP, Burman KD. Angiotensin-Converting Enzyme Activity and Thyroid Function Decrease Acutely in Critical Illness. *Clinical Research*, 32:253A, 1984.
63. Zaloga GP, Chernow B, Zajtchuk R, Hall K, Hargraves R, Burman KD, Smallridge R, Lake CR. Critical Illness Decreases Thyrotropin Responsiveness to Thyrotropin-releasing Hormone - A Potential Cause of Misinterpretation of Thyroid Function Tests in Critically Ill Patients. *Critical Care Medicine*, 12:235, 1984.
64. Burman KD, Smallridge RC, Wartofsky L. Iodide Administration Enhances Thyrotropin Responsiveness to TRH During Fasting: Evidence for Normal Pituitary Feedback Regulation. 7th International congress of Endocrinology, Quebec, Canada, A538, July 1984.
65. Burman KD, Luke Y, Wartofsky L, Djuh Y, Baker J Jr. Preparation of Biotinylated ReceptorPurified Graves' IgG: A Simple Technique Allowing Direct Functional Assessment of TSH Receptor Antibody Interaction with Membranes. Satellite Symposium, 7th International Congress of Endocrinology, *Journal of Steroid Biochemistry*, 20:L-29, June 1984.
66. Baker J Jr., Wright C, Sadoff J, Burman KD. The Development of Monoclonal Antibodies Directed against Anti-TSH Receptor Antibodies. Satellite Symposium, 7th International Congress of Endocrinology, Quebec, Canada, *Journal of Steroid Biochemistry*, 20:L-30, June 1984.
67. Burman KD, Baker Jr JR., Lukes YG, Djuh YY, Peters JB, Grandlund D, Dembrow D. Wartofsky L. Characterization of a Monoclonal Antibody Developed against the TSH Receptor. The American Thyroid Association, Sixtieth Meeting, New York, NY, T-25, Sep 1984.
68. Baker Jr JR, Raines KB, Lukes YG, Burman KD. Anti-TSH Antibodies in the Sera of Graves' Patients Which Display Anti-Idiotypic Activity against TSH Receptor Purified Graves' IgG. The American Thyroid Association, Sixtieth Meeting, New York, NY, T-37, Sep 1984.
69. Hennessey JV, Burman KD, Wartofsky LW. Equivalency of Two Brand Name L-thyroxine Preparation. Association of Military Physicians, Dayton, OH, Mar 1985.
70. Baker JR, Engler RJM, Burman KD, Djuh Y. Beta-adrenergic Binding Antibodies (BLA) in Adult, Steroid Dependent Asthmatics. Presented to American Academy of Allergy and Immunology, 1985.

71. Zuker a, Chernow B, Fields AI, Hung W, Burman KD. Evaluation of Thyroid Function in Critically Ill Children. Critical Care Medicine Meeting, 1985.
72. Baker Jr JR., Wartofsky L, Wortsman J, Burman KD. TSH Receptor Antibody and Antiidiotypic Antibody Containing Immune Complexes in Graves' Disease. Clinical Research, 33:307A, 1985.
73. Weetman AP, Volkman DJ, Burman KD, Margolick JB, Petrick P, Weintraub B, Fauci AS. Induction of Ia Antigens on Thyroid Cells and Autoantigen Presentations in Graves' Disease. Clinical Research, 33:391A, 1985.
74. Glass AR, Anderson J, Burman KD, Decreased Serum Triiodothyronine (T3) in Underfed Rats: Adaption to Chronic Calorie Deficiency. Clinical Research, 33:307A, 1985
75. Sack J, Baker Jr JR., Wartofsky L, Weetman AP, Volkman D. Margolick J, Burman KD. Natural Killer Cells in Hashimoto's Thyroiditis. Endocrine Society Program, Abstract 724, 1985.
76. Sack J, Baker Jr JR., Weetman AP, Wartofsky LW, Burman KD. The Role of Antibody Dependent Cytotoxicity and natural Killer Cells in Hashimoto's Disease. Presented at International Thyroid Meeting, Sao Paolo, Brazil, Sept., 1985
77. Whorton NE, Burman KD, Smallridge RC. Angiotensin-Converting Enzyme Activity, Reduced in Fasted Human, is not Corrected by T3 Administration. Endocrine Society, Abstract 1316, 1985.
78. Baker JR, Saunders, NB, Burman KD. Human Monoclonal Antibodies Derived from Peripheral blood Lymphocytes of Graves' Disease Patients which Inhibit both TSH and Graves' IgGmediated production of CAMP. Clinical Research. 34:433A, 1986.
79. Sack J, Burman KD, Dwyer D, Zilberstein D. Thyrotropin-binding Proteins in Leishmania: Serum Antibodies in Patients with Auto-immune Thyroid Disease Directed Against Specific Parasite Membrane Antigen. Clinical Research 34:433A, 1986.
80. Baker JR, Wartofsky L, Burman KD. Mouse Monoclonal Antibodies to Human Thyrocyte Membrane Proteins which Augment both TSH and Graves' IgG-mediated Production of Cyclic Adenosine Monophosphate (CAMP). Clinical Research 34:421A, 1986.
81. Miller FW, Baker Jr JR., Burman KD, Steinber AD. Thyroid-stimulating and Thyrotropin binding-inhibiting Immunoglobulins in Patients with Systemic Lupus Erythematosus (SLE). Proceedings of the International Congress of immunology, Toronto, July 1986.
82. Tseng Y-C, Burman KD, Baker JR, D'Avis J, Wartofsky L. Intrinsic Abnormality of Thyroid Cells from a Brobdingnagian Goiter. Endocrine Society Meeting, Abstract 834, 1986.
83. Sack J, Zilberstein D. Barile MF, Wartofsky L, Dwyer D, Burman KD. Characterization of Thyrotropin binding Proteins in Mycoplasma: Serum Antibodies Directed against a Specific Mycoplasma Membrane Determinant in Patients with Auto-immune Thyroid Disease. Endocrine Society Meeting, Abstract 834, 1986.84. Ahmann A., Baker JR, Weetman AP, Wartofsky L, Nutman T, Burman KD. Serum Immunoglobulins in Patients with Graves' Ophthalmopathy Directed against Unique Determinants in Porcine Eye Muscle. Clinical Research 34:420A, 1986.

84. Weetman AP, Nutman TB, Burman KD, Smallridge RC. Sustained Thyroid Autoimmunity in Subacute Thyroiditis (SAT). Fifth Joint Meeting of British Endocrine Societies, 1986 and European Thyroid Association, Stockholm, June 1986.
85. Weetman AP, Smallridge RC, Hayslip C, Burman KD. Multiple Autoantigenic Determinants in Thyroid Autoimmunity. International Symposium, Thyroid Autoimmunity, Pisa, Italy, November 1986 and European Thyroid Association, Stockholm 1986.
86. Weetman AP, Baker J, Burman KD. Thyroid Autoantigen Heterogeneity Demonstrated by Immunoblotting. Medical Research Society Meeting, Clinical Science. June 1987
87. Johnson K, Rinke W, Burman KD. Comparison of Circumference, Skinfold, Bioelectrical Impedance and Hydrodensitometry to Estimate Percent Body Fat during Weight Loss. FASEB Meeting, Spring 1987.
88. Reed HL, Bryce D, Shakir KM, Burman KD, O'Brian JT. Human Thyroidal and Cardiovascular Responses to Prolonged antarctic Residence. Federation Proceedings 46:332, 1987.
89. Kikendall JW, Burman KD, Johnson LF. Esophageal Function in Early Hypothyroidism. American Gastroenterology Association, 1987.
90. Burman KD, Djuh YY, LaRocca RV, Israel MA, Nunes ME, D'Avis JC, Nicholson DE, Helman LJ, Wartofsky, L. C-myc Expression in Normal, Adenomatous, and Cancerous Thyroid Tissue. Presented at American Thyroid Association National Meeting and Abstract, Washington, DC, Sept 1987
91. Tseng YC, Burman KD, D'Avis JC, Lahiri S. And Wartofsky L. Thyrotropin Enhances Epidermal Growth Factor Receptor in Intact Human Thyroid Cells. Endocrine Society 70th Annual Meeting, New Orleans, LA, June 1988.
92. Ahmann AJ, Tseng YC, Burman KD, Sellitti DF, Wartofsky L. [¹²⁵I] - Anriopeptin Binding to Cultured Porcine Thyrocytes: Influence of Iodine and Thyrotropin. 70th Annual Meeting Endocrine Society, New Orleans, LA, June 1988.
93. Baker Jr JR., Solomon BL, Saunders NB, Burman KD. The Failure of Immunotherapy using Intravenous IgG (IVIgG) to Alter the Hyperthyroidism of Graves' Disease. Clinical Research 36:382A, 1988.
94. Baker Jr JR., Saunders NB, Burman KD. A Single Human Monoclonal Antibody Derived from Lymphocytes of a Graves' Disease (GD) Patient with Activity of TBII, TSI and TGSI. Clinical Research 36:389A, 1988.
95. Reed HL, Kowalski K, Shakir KM, Burman KD, O'Brian JT, Lewis RB. Multiple Cold Air Exposures Elevate Serum Total and Low Density Lipoprotein Cholesterol in Euthyroid Men. Clinical Research 36:389A, 1988.
96. Tseng YL, Schaudies RP, Ahmann A, D'Avis J, Geelhoed GW, Burman KD, Wartofsky L. Effects of Epidermal Growth Factor (EGF) on Thyroglobulin (TG) and Cyclic AMP Production by Human Thyrocytes in Long-Term Cultures, American Thyroid Association Annual Meeting, Abstract 114, 1988.

97. Burman KD, Djuh YY, Kesler P, Baker JR, D'Avis JC. Analysis of Epidermal Growth Factor Receptor Gene (ERB-B) in Thyrocytes from Patient with Thyroid Disorders. 70th Annual Meeting Endocrine Society, New Orleans, LA, June 1988.
98. Burman KD, Djuh YY, Kesler P, Baker JR, D'Avis JC. Analysis of Thyroid Hormone Receptor Gene (c-erb A Beta) in Thyrocytes from Patient with Thyroid Disorders. Presented at 71st Annual Meeting Endocrine Society, Seattle, WA, June 1989.
99. Baker Jr., JR, Saunder NB, Polly SN, Landry F, Stricker RB, Burman KD. Identification of Thyroid Histones as Auto-Antigens Using Human Monoclonal Antibodies. Clinical Research 37:356A, 1989.
100. Polly SN, Saunders NB, Marry K, Stricker RB, Burman KD, Baker Jr., JR. Evaluation of the Binding characteristics of human Monoclonal Antibodies Directed Against Histones. Clinical Research 37:588A, 1989.
101. Tseng YL, Lahiri S, Sellitti DF, Burman KD, Wartofsky L. Atrial Natriuretic Peptide Inhibits Thyroglobulin Secretion from Human Thyroid Cells by Affinity Cross-Linking. 64th Annual Meeting, American Thyroid Association, San Francisco, CA, September 1989.
102. Tseng YL, Sellitti DF, Burman KD, Wartofsky L. Characterization of a Receptor for Atrial Natriuretic Peptide in Human Thyroid Cells by Affinity Cross-Linking. 64th Annual Meeting, American Thyroid Association, San Francisco, CA, Sept 1989.
103. Baker Jr., JR, Saunders NB, Stricker RB, Burman KD. Unusual Cytoplasmic Nucleoproteins are Autoantigens in Graves' Disease (GD). American Federation Clinical Research, 1989.
104. Fein HG, Burman KD, Djuh YY, Usala SJ, Smallridge RC. Linkage between the Syndrome of Generalized Thyroid Hormone Resistance (GTHR) and the Human C-erbA Gene is Present in Multiple Kindreds. American Thyroid Association, San Francisco, CA, Abstract 1, Sept 1989.
105. Burch HB, Lukes YG, Cai WY, Carr FE, Wartofsky L, Burman KD. A Novel Approach to the Identification of Uniquely Expressed Genes in Graves' Disease Thyroid Tissue. Clinical Research 38:264A, 1990.
106. Solomon B, Wartofsky L, Burman KD. Cholestyramine Treatment of Thyrotoxicosis. Endocrine Society, Abstract 329, June 1990.
107. Humphrey M, Mosca J, Baker JR, Drabick J, Carr FE, Burke D, Wartofsky L, Burman KD. Search for Retroviral DNA Sequences in Genomic DNA Isolated from Patients with Graves' Disease. Clinical Research 38:383A, 1990.
108. Peele M, Carr FE, Baker JR, Wartofsky L, Burman KD. Thyrotropin Gene Expression in Human Lymphocytes. Clinical Research 38:296A, 1990.
109. Hicks KA, Tseng YL, Lahiri S, Burman KD, D'Avis JC, Sellitti D, Wartofsky L. Thyrotropin Augments Internalization of the Atrial Natriuretic Peptide Receptor Complex in Thyrocytes. Endocrine Society, Abstract 729, June 1990.
110. Burman KD, Djuh YY, Nicholson D, Fein H, Usala S, Bradley WEC, Berard J, Wartofsky L. Identification of a Unique Mutation in Affected Members of a Family with the Syndrome of

- Generalized Thyroid Hormone Resistance. Endocrine Society Meeting, Washington, DC, Abstract 848, June 1991.
111. Nagy E, Burch H, Burman KD. TSH Reduces PHA Induced Lymphocyte Proliferation In Vitro. Endocrine Society Meeting, Washington, DC, Abstract 1232, June 1991.
 112. Jackson S, Tseng YL, Lahiri S, D'Avis JC, Burman KD, Wartofsky L. Endothelin and the Thyroid: Tissue Receptors and Clinical Correlates. *Clinical research* 39:207A, April 1991.
 113. Nagy E, Burch HB, Lukes YG, Burman KD. Investigations concerning an Immunogenic Epitope of the Human TSH Receptor. American Thyroid Association annual Meeting, Boston, MA, Abstract 63, Sept. 1991
 114. Burman KD, Lukes YG, Gemski P. Molecular Homology between the Human TSH Receptor and *Yersinia Enterocolitica*. American Thyroid Association Annual Meeting, Boston, MA, Abstract 122, Sept. 1991.
 115. Haibach H, Burns TW, Carlson HE, Burman KD, Deftos LJ. Cowden's Disease Associated with Merkel Cell Carcinoma and Renal Cell Carcinoma. *Clinical Research* 39:704a, October 1991.
 116. Nagy EV, Burch HB, Lukes YG, Burman KD. Lymphocyte Responsiveness to Immunogenic Peptides of the Human TSH Receptor. Endocrine Society Annual Meeting, Abstract 446, San Antonio, TX, June 1992
 117. Soloman B, and Burman KD. The Prevalence of Bone Fractures in Women with Thyroid Disease. Endocrine Society Annual Meeting, Abstract 424, San Antonio, TX, June 1992.
 118. Coffey L, Burman KD. Predicting Energy Expenditure Women with Gestational Diabetes Mellitus. Submitted, March 1992.
 119. Nagy EV, Burman KD. Graves' IgG Recognizes Linear Epitopes in the Human Thyrotropin Receptor. American Thyroid Association Annual Meeting, Rochester, MN, September 1992, Abstract 128.
 120. Burch HB, Sellitti D, Nagy E, Burman KD. Immunohistochemical Staining pattern of Human and Porcine Thyroid Cells with Sera Directed Against an Immunogenic Thyrotropin Receptor Peptide. American Thyroid Association Annual Meeting, Rochester, MN, Abstract 126, Sept. 1992.
 121. Burch HB, Barnes S, Sellitti D, Nagy E, Burman KD. Graves' Retroocular Fibroblasts Contain Protein Which is Immunogenically Related But not Identical to the Thyrotropin Receptor. 75th Annual Meeting, Endocrine Society, Las Vegas, NV, Abstract 131, 1993.
 122. Bhatia SK, Koppers RC, Ross NR, Saboori AM, Burch HB, Nagy EV, Burman KD. Thyroglobulin Epitopes Involved in Autoimmune Thyroid Disease. 75th Annual Meeting, Endocrine Society, Las Vegas, NV, Abstract 1279, 1993.
 123. Burman KD. Issues in Management of Thyroid Cancer: Should Radioiodine Scans Still be Performed? Plenary Lecture, Endocrine Society, Las Vegas, NV, 1993.

124. Solomon B, Wartofsky L, Burman KD. Management of Differentiated Thyroid Carcinoma: Results of a Survey of A.T.A. Members. Submitted, American Thyroid Association Annual Meeting, Tampa, FL, Abstract 67, Nov. 1993.
125. Nagy EV, Burch HB, Burman KD. Unidirectional Shift of the Dominant T Cell Epitope in the Human Thyrotropin Receptor in Graves' Disease. Submitted, American Thyroid Association Annual Meeting, Tampa, FL, Abstract 114, Nov. 1993.
126. Kalvaitis S, Burman KD, Pierce L, Buchly M, and Wartofsky L. Washington Hospital Center, Washington, DC. Successful treatment of a patient with thyroid storm: combined use of lithium, ipodate, cholestyramine and charcoa hemoperfusion. April 1995.
127. Atwa MA, Smallridge RC, Gist ID, AboHashem MB, El-Kannishy MB and Burman KD. Effects of bradykinin and TSH on phospholipase C and A₂ systems in Retroocular fibroblasts obtained from patients with Graves' Ophthalmopathy. 11th International Thyroid Congress, Toronto, Canada, September 10-15, 1995.
128. Ringel T, Taylor CE, Freter L, Diehl R, Howard R, and Burman KD. Hodgkin's Disease is associated with increased antibody cellular cytotoxicity against human orbital muscle cells (ADCC). 11th International Thyroid Congress, September 10-15, 1995, Toronto, Canada.
129. Solomon RL, Cranston T, McDermott MT, ASP A, Burman KD. Treatment of Graves' Disease with Cholestyramine. The Endocrine Society, Washington, DC, January 1995.
130. Ringel MD, Carr FE, Nicholson D, and Burman KD. Endogenous mutant p53 binds p53-specific binding sites and data binding protein in thyroid carcinoma cells. The Endocrine Society, Washington, DC, January 1995.
131. Burman KD, Atwa M, Kiang JC, Gist ID, Rui L, Lahn R, Smallridge RC. Evidence for the involvement of protein kinase C (PKC) isoforms in the proliferation of retro ocular fibroblasts (ROF) obtained from patients with Graves' Ophthalmopathy. 10th International Congress of Endocrinology, Washington, DC, January 1996.
132. Smallridge RC, Porter L, Burman KD, Cranston T, Tsokos GC and Solomon BL. Soluble interleukin-2 receptor (sIL2R) is an early response marker in the treatment of thyrotoxicosis. 10th International Congress of Endocrinology, Washington, DC, January 1996.
133. Torrens J, Bernet V, Mahoney K, Solomon B, Burman KD, Wartofsky L, Duncan W. Cycle etidronate increases lumbar spine bone mineral density (LS BMD) of women taking Levothyroxine. 10th International Congress of Endocrinology, Washington, DC, January 1996.
134. Kalvaitis S, Burman KD, Perry D, Wartofsky L. Ret oncogene testing for medullary cancer: a clinically relevant advance. American College of Physicians, 1996 National Associates Competition, Clinical Vignette Paper Competition Winner, Philadelphia, PA.
135. Tseng Y, Lahiri S, Nicholson D, Burman KD and Wartofsky L. Evidence of an association of endothelin-1 receptor expression to the active growth phase of the cell cycle and identification of endothelin-1 mRNA in FRTL5 cells. *Endocrinol & Metab*, 1996, 3, 37-47.

136. Karl M, Ellahham S, Oskoui R, Wartofsky L and Burman KD. Thyrotoxicosis associated with rapidly reversible low-output heart failure and dilated cardiomyopathy. Poster presentation. 79th Annual Meeting of the Endocrine Society, Minneapolis, MN. June 1997.
137. Lu R, Wartofsky L, Bahn R, Garrity J, Sutton BD and Burman KD. Role of oxygen free radicals in IL-1B-induced glycosaminoglycan production by retroocular fibroblasts from patients with Graves' Ophthalmopathy. Poster presentation. 79th annual Meeting of the Endocrine Society, Minneapolis, MN, June 1997.
138. Rahmaniyan M, Burman, KD, Lando HM. Occurrence of an invasive papillary thyroid carcinoma in a hyperfunctioning nodule. Endocrine Society Annual Meeting. Poster
139. Prendiville S, Burman KD, Ringel MD, Shmookler BM, Deeb ZE, Wolfe K, Azumi N, Wartofsky L, Sessions RB. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Presentation. Annual meeting of Otolaryngology-Head and Neck Surgery, San Antonio, TX. September 1998.
140. Lu R, PV Balducci-Silano, Ringel MD, Ress J, Bahn RS, Garrity J, Wartofsky L, Tsokos GC, Burman, KD. Modulation of Fas/Fas ligand expression in retro ocular fibroblasts from patient with Graves' Ophthalmopathy. Poster presentation at the Annual Endocrine Society, pp 3-205, June 1998.
141. Gardner R, Tuttle R, Burman KD, Haddady S, Truman C, Wartofsky L, Sessions R, Ringel M. Intra thyroidal and extra thyroidal vascular invasion are associated with distant metastasis at diagnosis and tumor recurrence in papillary thyroid carcinoma. 71st annual Meeting of the American Thyroid Association, Abstract 171, September 1998.
142. Ringel M, Balducci-Silano P, Tuttle R, Djuh Y, Anderson J, Burman KD, Wartofsky L, Silverman J, Kazarosyan M, Spencer c, Ladenson P, Levine M. Quantitative thyroglobulin RTPCR detection of recurrent or residual thyroid carcinoma in patients with anti-thyroglobulin antibodies. 71st Annual Meeting of the American Thyroid Association, Abstract 169, September 1998.
143. Lu R, Balducci-Silano PL, Ringel MD, Vodovitz Y, Burman KD. Fas, Fas ligand expression and Fas-mediated apoptosis in human retro ocular fibroblasts. Endocrine Society Annual Meeting, 1-343, June 1999.
144. Balducci-Silano PL, Lu R, Burman KD, Ringel MD, Thyroid cancer cells express Fas and Fas ligand but are resistant Fas-mediated apoptosis. Endocrine Society Annual Meeting, 1-589, June 1999.
145. Ringel MD, Balducci-Silano PL, Anderson JS, Spencer CA, Silverman J, Sparling YH, Burman KD, Wartofsky L, Ladenson PW, Levine MA, Tuttle RM. Clinical evaluation of quantitative thyroglobulin PCR and immunoassay in 107 patients with thyroid cancer. Endocrine Society Annual Meeting, 2-718, June 1999.
146. Suzuki K, Moriyama E, Mori-Aoki A, Katoh R, Royaux LA, Green RD, Kohn LD, Burman KD. Pendred syndrome gene, PDS, is an apical porter of iodide and its expression is tightly regulated by follicular thyroglobulin. Presented at the annual meeting of the American Thyroid Association, September 1999.

147. Greenberg M, Chen X, Hayre N, Suzuki K, Saji M, Priebat D, Burman KD, Ringel MD. Cytotoxic activity of 2', 2'-difluorodeosycytidine (Gemcitabine) against poorly differentiated human thyroid carcinoma cells. Endocrine Society, 2000.
148. Ringel MD, Daniels M, Hayre N, Burch H, Bernet V, Savnier B, Shuppert F, Wartofsky L, Burman KD, Kohn LD, Saji M. Over expression and over activation of AKT in thyroid carcinoma. Presented at the International Thyroid Congress, Kyoto, Japan October 2000.
149. Ringel MD, Bernet V, Burch H, Schuppert F, Burman KD, Saji M. Overexpression of a Metastasis Inhibiting Receptor (Metastin Receptor) in Papillary, but not Follicular, Thyroid Carcinoma. American Thyroid Association, November, 2001
150. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M. Overexpression and Overactivation of Akt in Thyroid Carcinoma. American Thyroid Association, November 2001.
151. Hayre N, Peck G, Nigra T, Bixby K, Saji M, Burman KD, Ringel MD. Detection of circulating malignant melanoma cells in peripheral blood by real-time PCR assay. American Academy of Dermatology, 2001.
152. Chen XW, Saji M, Balducci-Silano P, Hayre N, Spencer CA, Burman KD, Ringel MD. Recombinant human thyrotropin stimulation of circulating thyroglobulin mrna in patients with thyroid cancer. American Thyroid Association, November 2001.
153. Miyagi E, Saji M, Burman KD, Singer D, Ringel MD. Stable expression of Ret/PTC 3 in FRTL5 thyroid cells enhances basal and insulin-stimulated activation of Akt. American Thyroid Association November 2001.
154. Vaishnav Y, Anderson J, Adair C, Rheinhardt B, Saji M, Burman KD, Burch H, Ringel MD, Bernet VJ. Is BAG-1 a useful molecular marker in the differentiation of thyroid cancer from benign thyroid nodules? American Thyroid Association, November 2001.
155. Otteson T, Burman KD, Ringel MD, Krishnan J. Proto-Oncogene Positivity in Medullary Thyroid Carcinoma, October 2002, Academy of Otolaryngology.
156. Stathatos N, Saji M, Vasko V, Burman KD, Ringel MD. Metastatin activation inhibits migration and growth of thyroid cancer cells in vitro. Endocrine Society Annual Meeting, Philadelphia, PA, 2003.
157. Burningham AR, Krishnan, J, Davidson BJ, Ringel MD, Burman KD. Papillary and Follicular Variant of Papillary Carcinoma of the Thyroid: Initial Presentation and Response to Therapy, October 2004, Academy of Otolaryngology.
158. Stathatos N, Bourdeau I, Saji M, Vasko V, Bauer A, Burman KD, Stratakis C, Ringel MD. Metastatin Receptor (GPR54) Activation inhibits Growth and Migration of Thyroid Cancer Cells and Increases Expression of Endogenous Akt and Calcineurin Inhibitors. Endocrine Society Presentation, June, 2004, New Orleans, LA.
159. Vasko V, Kato Y, Saji M, Cheng SY, Burman KD, Ringel MD. Selective Activation of Akt in Thyroid Cancers in TR beta pv/pv Mice. Endocrine Society Presentation, June, 2004, New Orleans, LA.

160. Ly T, Bhagati R, Jarrett J, Tran K, Burman KD. Glucocorticoid Induced Osteoporosis: Implementation of Prophylaxis and Practice Patterns. May 2005, Submitted to *American College of Rheumatology*.
161. Diez JJ, Iglesias P, Burman KD. Spontaneous normalization of thyrotropin concentrations in patients with subclinical hypothyroidism. Endocrine Society, June 2005.
162. Atkins FB, Van Nostrand D, Kulkarni K, Burman KD, Wartofsky L. The Frequency with which Empiric Amounts of Radioiodine “Over-” or “Under-” treat Patients with Metastatic Well-Differentiated Thyroid Cancer. *J Nucl Med* 2005;46:129P.
163. VanNostrand D, Atkins F, Kulkarni K, Burman KD, Wartofsky L. The Utility of Percent 48-Hour Whole body Retention for Modifying Empiric Amounts of I-131 for the Treatment of Thyroid Carcinoma. Society of Nuclear Medicine, San Diego, CA 2006.
164. Vasko V, Hodak S, Russell R, Francis G, Saji M, Ringel M, Burman KD. Cancer Cell- Cancer Cell Paracrine Interactions are Important for Thyroid Cancer Invasion. Endocrine Society, June 2006
165. Kantorovich V, Coppotelli G, Krishnan J, Skarulis M, Celi F, Burman KD. Expression of GLUT Transporters in Metastatic Thyroid Cancer and Correlation with PET Scan. Endocrine Society, June 2006
166. Burman KD, Seiboth, VanNostrand D, Wartofsky L, Jonklaas J. Analysis of the Role of PET/MRI Digital Fusion Images in Detection and Management of Recurrent of Persistent Thyroid Cancer. Endocrine Society, June 2006
167. Van Nostrand D, Atkins F, Kulkarni K, Burman KD, and Wartofsky L. The Utility of Percent 48Hour Whole Body Retention for Modifying Empiric Amounts of I-131 for the Treatment of Thyroid Carcinoma. *J Nucl Med*, (abstract). 2006;7(1):324P.
168. Esposito G, Van Nostrand D, Atkins F, Burman KD, Wartofsky L, Kulkarni, K. Frequency of “Over” And “Under” Treatment with Empiric Dosage of I-131 in Patients with and without Lung Metastasis Secondary to Well-Differentiated Thyroid Cancer *J Nucl Med*, (abstract) 2006;47(1):238P
169. Vasko V, Bauer A, Patel A, Kinichenko V, Larin A, Saji M, Ringel M, DeMicco C, Hodak S, and Burman KD. Thyroid Cancer Metastases are Associated with Gain of Stem Cell Markers Expression. Endocrine Society, June 2007.
170. Acio E, Van Nostrand D, Moreau S, Seiboth L, Burman KD. The utility of the interpretation of PET-MR simultaneously versus independent of each other in patients with well-differentiated thyroid cancer. *J Nucl Med* 2007.
171. Aiken M, Van Nostrand D, Kulkarni K, Garcia C, Acio E, Boyle L, Burman KD. The utility of 123-I scans in the identification of parathyroid adenomas and/or hyperplasia with rapid 99m-Tc sestamibi washout. *J Nucl Med* 2007.
172. Bandarul VVN, Van Nostrand D, Burman KD, Wartofsky L. Selecting 131-I dosage (activity)for the ablation and treatment of patients with well-differentiated thyroid cancer. *J Nucl Med* 2007.

173. Van Nostrand D, Atkins F, Garcia C, Moreau S, Burman KD, Wartofsky L. Radiopharmacokinetics of radioiodine in the salivary glands after lemon juice: a case report. *J Nucl Med* 2007.
174. Van Nostrand D, Aiken M, Atkins F, Esposito G, Moreau S, Garcia C, Acio E, Burman KD, Wartofsky L. The utility of radioiodine whole body scans prior to 131-I ablation in patients with well-differentiated thyroid cancer. *J Nucl Med*, 2007.
175. Atkins F, Van Nostrand D, Moreau S, Burman KD, Wartofsky L. Percent 48-hr whole body retention for estimating maximum tolerated activity of 131-I for the treatment of well-differentiated thyroid cancer: The effect of rhTSH stimulation vs thyroid hormone withdrawal on a bi-exponential dosimetry model. *J Nucl Med*, 2007.
176. Vasko V, Bauer A, Patel A, Kinichenko V, Larin A, Saji M, Ringel MD, Garcia S, DeMicco, Hodak S, Burman KD. Thyroid Cancer metastases are associated with gain of stem cell marker expression. Endocrine Society, Toronto, Canada, June, 07.
177. Aiken M, Shin Y-R, Kulkarni K, Van Nostrand D, Burman KD; Wartofsky L. Quantitating the superiority of pinhole relative to parallel hole collimator images in detecting foci of radioiodine uptake in the thyroid bed/neck in patients with well-differentiated thyroid cancer. 55th Society of Nuclear Medicine Annual Meeting, New Orleans, LA, June 2008.
178. Wells KJ, Moreau S, Shin YR, Van Nostrand D, Burman KD, Wartofsky L. Predictive factors for and the frequency of positive (+) post-treatment (tx) scans after the radioiodine (RAI) tx of patients with well-differentiated thyroid cancer (WDTC), positive serum thyroglobulin levels (TG+), and negative diagnostic (dx) RAI whole body scans (WBS-). Society of Nuclear Medicine, June 2008.
179. Wells KJ, Moreau S, Shin, YR, Aiken M, Van Nostrand, D, Burman, KD, Wartofsky L. To treat or not to treat “thyroglobulin-positive and radioiodine diagnostic whole body scan negative” patients with well-differentiated thyroid cancer: an educational exhibit. Society of Nuclear Medicine, June 2008.
180. Bandaru VV, Shin Y-R, Van Nostrand D, Burman KD, Wartofsky L. The prognostic significance of pulmonary findings on diagnostic imaging modalities in patients with pulmonary metastases secondary to well-differentiated thyroid cancer: An educational exhibit. Society of Nuclear Medicine, June 2008.
181. Shin YR, Bandaru V, Van Nostrand D, Moreau S, Burman KD, Wartofsky L. The frequency of heterogeneous uptake and/or hypofunctioning areas on thyroid scintigraphy in patients with Graves' Disease. Society of Nuclear Medicine, June 2008.
182. Shin YR, Kulkarni K, Aiken M, Bandaru V, Wells K, Boyle L, Burman KD, Van Nostrand D. The utility of 123-I subtraction scan (S-scan) combined with dual-time-point (DTP) 99m-Tc sestamibi (MIBI) scan in the identification of parathyroid adenomas (PA) and/or hyperplasia (PH) that were negative or indeterminate on DTP MIBI scan alone. Society of Nuclear Medicine, June 2008.

183. Van Nostrand D, Moreau S, Atkins F, Shin YR, Burman KD, Wartofsky L. I-124 versus I-131 in the identification of suspected residual thyroid tissue or metastasis in patients with well-differentiated thyroid cancer (WDTC). Society of Nuclear Medicine, June 2008.
184. FB Atkins, Van Nostrand D, Butler C, OComparison of the blood biokinetics of I-124 and I-131 in patients with well-differentiated thyroid cancer (WDTC). Society of Nuclear Medicine, June 2008.
185. Manes RP, Wartofsky L, Stathatos NA, Burman KD, Deeb ZE, Chia SH. Thyroglossal Duct Carcinoma, ENT Meeting, 2008
186. Harwick M, Burman KD. Analysis of the Translocator Protein (TSPO) in Thyroid Cancer Cell Lines. American Thyroid Association Meeting, Chicago, IL, October, 2008.
187. Loh JA, Wartofsky L, Jonklaas J, Burman KD. Levothyroxine therapy during pregnancy. Endocrine Society, San Francisco, CA. June, 08.
188. Nadkarni PJ, Burman KD. Propylthiouracil-Induced Fulminant Hepatic Failure. Endocrine Society, San Francisco, CA. June, 08.
189. G. Khorjekar, D. Van Nostrand, A. Acio, S. Chennupati, K. Prasad, K. Kulkarni, K. Burman. Locations and patterns of frequent, infrequent, and rare sites of metastasis secondary to well-differentiated thyroid cancer. Society of Nuclear Medicine 2010.
190. G. Khorjekar, D. Van Nostrand, S. Moreau, F. Atkins, M. Mete, K. Burman, L. Wartofsky. Survival rate in patients diagnosed with well-differentiated thyroid cancer with bone metastases the Washington Hospital Center Experience. Society of Nuclear Medicine 2010.
191. G. Khorjekar, D. Van Nostrand, K. Kulkarni, C. Garcia, S. Moreau, A. Ansari, K. Prasad, K. Burman. Pilot study assessing factors altering radioiodine uptake in breast tissue in patients with well-differentiated thyroid cancer. Society of Nuclear Medicine 2010..
192. Burman, K. The frequency of parathyroid adenomas and/or hyperplasia that have washout equal to normal thyroid tissue in patients who have a negative dual-time-point ^{99m}Tc sestamibi scans. Society of Nuclear Medicine 2010.
193. Iyengar, K., Burman, K. Utility of Low Concentrations of Serum Thyroglobulin in Predicting Residual or Recurrent Disease in Patients Treated for Well-differentiated Thyroid Cancer. Endocrine Society, Annual Meeting, San Diego, CA.
194. Klubo-Gwiedzinska, J, Burman, K, Van Nostrand, D, Wartofsky, L. An undetectable initial rhTSH-stimulated Tg levels 12 months after the initial treatment of thyroid cancer serves as a good but not infallible indicator for cure. Endocrine Society, Annual Meeting, San Diego, CA.
195. Singla, S, Gogineni, J, Wartofsky, L, Burman, K. Prediction of Malignancy In Nodular Thyroid Disease by Serum Thyroglobulin (Tg) Measurement. Endocrine Society, Annual Meeting, San Diego, CA 2010.
196. Wartofsky, L, Burman, K. An undetectable initial rhTSH-stimulated Tg levels 12 months after the initial treatment of thyroid cancer serves as a good but not infallible indicator for cure. Endocrine Society, San Diego, CA 2010
Jonklaas, J, Burman, K. Age and the TSH Response to

- Hypothyroxinemia and Recombinant Thyrotropin. Endocrine Society, Annual Meeting, San Diego, CA 2010.
197. Kureti V, Burman K, Wexler J. Graves' disease complicated by paralysis and anterior mediastinal mass. National ACP Toronto, Canada.
 198. Reutemann, P, Ogram, A, Burman, K, Lockshin, B, Dugan, E. A Solitary Cutaneous Metastasis from Papillary Thyroid Adenocarcinoma. American Academy of Dermatology, August 2010.
 199. Khorjekar G¹, Van Nostrand D¹, Kharazi P¹, Moreau S¹, Atkins F¹, Chennupati S¹, Mete M⁴, Burman K², Wartofsky L. 124I PET versus 131I planar imaging in the identification of functioning residual thyroid tissue and/or metastases in patients with differentiated thyroid cancer: Update of Initial report. submitted to Society of Nuclear Medicine annual meeting, 2010.
 200. Klubo-Gwiedzinska J, Costello J, Jr, Jensen K, Burman KD, Wartofsky L, Vasko VV. Metformin Activates AMPK and Inhibits Thyroid Cancer Cell Growth in an Oncogene-Specific Manner. Endocrine Society, Annual Meeting, Boston, MA 2011.
 201. Klubo-Gwiedzinska J, Burman KD, Van Nostrand D, Mete M, Wartofsky L. Preparation with Recombinant Human Thyrotropin (rhTSH) Stimulation or Levothyroxine (T4) Withdrawal for Radioiodine (RAI) Treatment Gives Comparable Results in Patients with Metastatic Differentiated Thyroid Cancer (DTC). Endocrine Society, Annual Meeting, Boston, MA 2011.
 202. Klubo-Gwiedzinska J, Burman KD. Metformin Inhibits Anaplastic Thyroid Cancer Cells Growth through AMPK-dependent Down-regulation of mTOR/6SK Signaling. 81st Annual Meeting of the American Thyroid Association, Indian Wells, CA October 2011.
 203. Sathasivam A, Shapiro S, Pehlivanova M, Rapaport R, Burman K. Factors Associated with a Pubertal Response to Leuprolide Stimulation in Females with Suspected Central Precocious Puberty. Endocrine Society poster presentation at ENDO 2011, June 2011 Boston, MA.
 204. Khorjekar G, Burman K. The relationship of 123I breast uptake on thyroid scan to thyroid stimulating immunoglobulin in hyperthyroid patients: A pilot study Submitted January 2011.
 205. Burman K. Does Lemon Juice Increase Radioiodine Re-Accumulation within the Parotid Glands Greater Than If Lemon Juice Had Not Been Administered? Submitted to Annual Meeting Society of Nuclear Medicine, 2011.
 206. Schneider MT, Garcia C, O'Neil J, Van Nostrand D, Wexler J, Burman K, Wartofsky L. Retrospective Study of the Utility of ¹⁸F Sodium Fluoride PET Bone Scans in Patients with Thyroid Cancer. Submitted to the SNM Annual Meeting, held June 2012, Miami, FL
 207. Khorjekar G, Burman K. Does a negative diagnostic 131I planar scan AND 124I PET scan in patients with elevated Tg exclude 131I uptake on 131I post-therapy scan? Updated Results, submitted to the SNM Annual Meeting, held June 2012, Miami, FL
 208. Klubo-Gwiedzinska J, Jensen K, Costello Jr J, Patel A, Bauer A, Burman K, Wartofsky L, and Vasko V. Metformin Inhibits Growth and Decrease Resistance to Anoikis in Medullary Thyroid Cancer Cells. The Endocrine Society 2012

209. Khorjekar G, Burman K. Does a negative diagnostic ¹³¹I planar scan AND ¹²⁴I PET scan in patients with elevated Tg exclude ¹³¹I uptake on ¹³¹I post-therapy scan? Updated Results, SNM Annual Meeting, held June 2012, Miami, FL
210. Klubo-Gwiedzinska J, Jensen K, Costello Jr J, Patel A, Bauer A, Burman K, Wartofsky L, and Vasko V. Metformin Inhibits Growth and Decrease Resistance to Anoikis in Medullary Thyroid Cancer Cells. The Endocrine Society 2012.
211. Kushchayeva Y, Costello J, Carroll N, Boyle L, Burman K, Vasko V. Nelfinavir, a HIV protease inhibitor, induces growth arrest and apoptosis in medullary thyroid cancer cells via inhibition of RET kinase signaling. Presentation at International Thyroid Oncology Group. May 2013.
212. Kushchayeva Y, Kushchayev S, Carroll N, Felger E, Burman K, Boyle L. Spinal Metastases Secondary to Follicular (FTC) and Papillary (PTC) Thyroid Carcinomas: A Comparative Analysis of 174 cases. Presentation at International Thyroid Oncology Group. May 2013.
213. Klubo-Gwiedzinska J, John Costello, Jr, Aneeta Patel, Andrew Jacob Bauer, Kirk Ernest Jensen, Mihriye Mete, Kenneth Burman and Leonard Wartofsky Treatment with Metformin is Associated with Higher Remission Rate in Diabetic Patients with Thyroid Cancer. Endocrine Society, San Francisco, CA. June, 2013.
214. Popoveniuc G, Tanu Chandra, Meeta B Sharma, Marc R Blackman, Kenneth Burman and Leonard Wartofsky. Establishment of a Diagnostic Scoring System for Patients with Myxedema Coma. Endocrine Society, San Francisco, CA. June, 2013.
215. Popoveniuc G, Kenneth Burman, Jacqueline Jonklaas, Uha Prabhakar Reddy and Shannon Danielle Sullivan. Comparison of empiric versus individualized levothyroxine (LT4) dose adjustment in hypothyroid women during pregnancy: interim data analysis. Endocrine Society, San Francisco, CA. June, 2013.
216. Kushchayeva Y John Costello, Erin Felger, Lisa Boyle, Kenneth Burman and Vasyl Vasko. The HIV protease inhibitor Nelfinavir down-regulates p70S6K/S6 signaling, induce autophagy and apoptosis in thyroid cancer cells. Endocrine Society, San Francisco, CA. June, 2013. Brackbill AJ, Kenneth Burman, David S Cooper and Henry B Burch The Effect of Geographical Location in the United States on the Management of Graves' Disease Endocrine Society, San Francisco, CA. June, 2013.
217. Jonklaas J, Sathasivam I A, Wang H, Finigan D, Gu J, Soldin OP, Burman KD, Soldin S. Thyroid hormone measurements: Discrepancies between mass spectrometry and immunoassay. American Thyroid Association Annual Meeting, San Juan, Puerto Rico. October 2013.
218. Choudary C, Burman KD. Thyroid bed nodules on ultrasonography. American Thyroid Association Annual Meeting, San Juan, Puerto Rico. October 2013.
219. Soldin OP, Melvin C, Burman KD, Younis I. Unique studies of levothyroxine pharmacokinetics in the elderly. American Thyroid Association Annual Meeting, San Juan, Puerto Rico. October 2013.
220. Kuschchayeva Y, Kuschchayeva S, Carroll N, Felger E, Burman KD, Boyle L. Comparative analysis of follicular and papillary thyroid carcinoma spinal metastases. American Thyroid Association Annual Meeting, San Juan, Puerto Rico. October 2013.

221. Bikas A, Jensen K, Costello J, Patel A, Burman K and Vasko V. Expression of Organic Cation Transporter 1 (OCT1) in Medullary Thyroid Cancer. Presented, 84th Annual Meeting of the American Thyroid Association, San Diego, CA. November, 2014.
222. Bikas A, Burman K, Desale S, Mete M, Wartofsky L, Van Nostrand D. Effects of Dosimetry Guided ¹³¹I Therapy for Metastatic Differentiated Thyroid Cancer on Complete Blood Counts. Presentation 97th Annual Meeting The Endocrine Society. March, 2015.
223. Bikas A, Jensen K, Costello J, Patel A, Burman K and V. Vasko. Glucose Concentration Underlies the Efficacy of Treatment with Metformin in Thyroid Cancer Cells. Presentation (97th Annual Meeting of the Endocrine Society. San Diego. March, 2015.
224. Bikas A, Van Nostrand D, Jensen K, Desale S, Mete M, Wartofsky L, Vasko V, Burman K. Metformin Attenuates ¹³¹I – Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. Baltimore, MD. 2015.
225. Bethancourt E, Van Nostrand D, Orquiza M, Bloom G, Bikas A, Burman K, Wartofsky L. The public sites and the frequency of detection of patients treated with I-131 and the security management of those patients: the final report of a national survey. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. Baltimore, MD. 2015.
226. Bethancourt E, Van Nostrand D, Orquiza M, Bloom G, Bikas A, Burman K, Wartofsky L. The frequency and content of documents issued for patients' ¹³¹I therapies for security agents: the final report of a national survey. Society of Nuclear Medicine and Molecular Imaging Annual Meeting. Baltimore, MD. 2015.
227. A. Bikas, P. Kundra, J. Wexler, M. Mete, S. Desale, L. Wray, C. Barrett, B. Clark, L. Wartofsky, K. Burman. Phase II Clinical Trial of Sunitinib as Adjunctive Treatment in Patients with Advanced Differentiated Thyroid Cancer. 97th Annual Meeting of the Endocrine Society. March, 2015.
228. E. Bethancourt, D. Van Nostrand, M. Orquiza, G. Bloom, A. Bikas, K. Burman, L. Wartofsky. The public sites and the frequency of detection of patients treated with I-131 and the security management of those patients: the final report of a national survey. Presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2015 – Baltimore, MD – 6/2015)
229. Bethancourt, D. Van Nostrand, M. Orquiza, G. Bloom, A. Bikas, K. Burman, L. Wartofsky. The frequency and content of documents issued for patients' ¹³¹I therapies for security agents: the final report of a national survey. Presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2015 – Baltimore, MD – 6/2015)
230. A. Bikas, K. Jensen, J. Costello, A. Patel, L. Wartofsky, K. Burman, V. Vasko. The Oncotic Death Pathway in Thyroid Cancer Cells. Presented at the 15th International Thyroid Congress (Orlando, FL – 10/2015)

231. I. Singh, A. Bikas, C. Garcia, D. Van Nostrand, S. Desale, L. Wartofsky, K. Burman. Relation between 18FDG-PET SUV and size of lesions in thyroid carcinoma. Presented at the 15th International Thyroid Congress (Orlando, FL – 10/2015)
232. K. Jensen, A. Bikas, J. Costello, A. Patel, K. Burman, V. Vasko. Inhibition of mitochondrial complex 4 increases glucose consumption in thyroid cancer cells. Presented at the 15th International Thyroid Congress (Orlando, FL – 10/2015)
233. Y. Kuschayeva, K. Jensen, A. Bikas, J. Costello, A. Patel, K. Burman, V. Vasko. The Role of Autophagy in Thyroid Cancer Cells Response to the Treatment with HIV Protease Inhibitor Nelfinavir. Presented at the 15th International Thyroid Congress (Orlando, FL – 10/2015)
234. A. Bikas, A. Boulougoura, F. Mirza, S. Vachhani, L. Wartofsky, D. Van Nostrand, K. Burman. The Metabolic Profile Post a Dosimetry-Guided I-131 Therapy in Patients with Metastatic Differentiated Thyroid Cancer. Will be presented at the 98th Annual Meeting of the Endocrine Society – ENDO 2016 (Boston, MA – 4/2016)
235. A. Bikas, K. Jensen, A. Patel, J. Costello, L. Wartofsky, K. Burman, V. Vasko. High Glucose Decreases the Anti-Neoplastic Efficacy of Metformin in Medullary Thyroid Cancer Cells. Will be presented at the 98th Annual Meeting of the Endocrine Society – ENDO 2016 (Boston, MA – 4/2016)
236. Bikas A, Jensen K, Patel A, Costello J, Tkave R, Wartofsky L, Burman KD, Vasko V. The Role of Autophagy Regulator LC3B in Thyroid Cancer Cells Response to Metabolic Stress and Radiation. Poster 310. American Thyroid Association Annual Meeting, Denver, CO. March, 2016.
237. Parikh T, Shmouni FH, Burman KD, Carroll N, Sharma M, Sidhu, S. Spontaneous Intrathyroidal Hemorrhage Precipitated by Anticoagulation Therapy Resulting in Acute Respiratory Failure. Poster 251. American Thyroid Association Annual Meeting, Denver, CO. March, 2016.
238. A. Bikas, K. Jensen, J. Costello, A. Patel, K. Burman and V. Vasko Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells. Endocrine Society Meeting, Apr. 2017.
239. Gomes-Lima CJ, Nikiforov YE, Burman KD. Two Different Mutations in Coexistent Papillary Thyroid Carcinoma in Both Struma Ovarii and in the Thyroid Gland. Invited to compete in the Endocrine Society's Presidential Poster Competition for a first-authored top-scoring abstract for presentation at the Annual Meeting & Expo. Endocrine Society 99th Annual Meeting, Orlando, FL, 2017.
240. Wu D, Turner D, Burman K, Wartofsky L, Van Nostrand D. Checklist of criteria for the systematic assessment of patient-management guideline development. Journal of Nuclear Medicine. SNMMI 2017 Annual Meeting, Denver, CO.
241. Wu D, Lima CJ, Turner D, Burman K, Van Nostrand D. Radioiodine refractory differentiated thyroid cancer classifications and evolution. SNMMI 2017 Annual Meeting, Denver, CO.
242. Wu D, Turner D, Burman K, Wartofsky L, Van Nostrand D. Checklist of criteria for the systematic assessment of patient-management guideline development. *Featured Poster for Poster Competition*. SNMMI 2017 Annual Meeting, Denver, CO.

243. Wu D, Gomes Lima C, Moreau S, Kulkarni K, Zeymo A, Burman K, Wartofsky L, Van Nostrand D. Overall survival rate of patients with differentiated thyroid cancer bone metastasis. 3rd World Congress on Thyroid Cancer, Boston, MA, 2017.
244. Wu D, Turner D, Orquiza M, Burman K, Wartofsky L, Van Nostrand D. Sialoadenitis and xerostomia secondary to I-131 therapy in patients with differentiated thyroid cancer and who took sialagogues: a prospective study. 3rd World Congress on Thyroid Cancer, Boston, MA, 2017.
245. Costello J, Klubo-Gwiezdzinska J, Bikas A, Burman KD, Vasko V. Digital PCR is a powerful technique to detect BRAF mutation in patients with thyroid cancer. 87th Annual American Thyroid Association, October 2017, Victoria, Canada.
246. Turner D, Wu D, Burman KD, Wartofsky L, Van Nostrand D. Low-iodine diet and urine iodine measurements for 131-I treatments in patients with differentiated thyroid cancer: A comparison of 18 clinical practice guidelines. 87th Annual American Thyroid Association, October 2017, Victoria, Canada.
247. Kleess L, Kadambi P, Burman KD. An uncommon case of Cowden syndrome. 87th Annual American Thyroid Association, October 2017, Victoria, Canada.
248. Gomes-Lima CJ, Wu D, Hritani R, Punukollu S, Rao S, Zeymo A, Deeb H, Mete D, Van Nostrand D, Jonklaas J, Burman KD. Brain metastases from differentiated thyroid carcinoma: Current therapies and outcomes. 87th Annual American Thyroid Association, October 2017, Victoria, Canada.
249. Luo H, Tobey A, Auh S, Cochran C, Zemskova M, Gomes Lima CJ, Van Nostrand D, Burman KD, Wartofsky L, Van Nostrand D. Pretreatment with Lithium may be associated with improved overall survival in patients undergoing dosimetry-based radioactive iodine treatment for metastatic differentiated thyroid carcinoma. 87th Annual American Thyroid Association, October 2017, Victoria, Canada.
250. Wu D, Gomes Lima C, Moreau S, Kulkarni K, Zeymo A, Burman KD, Wartofsky L, Van Nostrand D. Prognostic factors in the overall survival rate of patients with differentiated thyroid cancer bone metastases. 87th Annual American Thyroid Association, October 2017, Victoria, Canada.
251. Wu D, Khorjekar G, Kharazi P, Zeymo A, Burman KD, Wartofsky L, Van Nostrand D. Xerophthalmia and epiphora secondary to 131-I therapy in patients with differentiated thyroid cancer: A prospective study. 87th Annual American Thyroid Association, October 2017, Victoria, Canada.
252. Burman KD. Controversies in Radioactive Iodine Adjuvant Therapy: Which patients? How much to give? Lecture at the Endocrine Society 100th Annual Meeting, Chicago, IL, 2018.
253. Patel A, Jensen KE, Mendonca-Torres M, Costello J, Hoperia V, Thakur S, KluboGwiezdzinska J, Bikas A, Burman KD, Vasko VV. Targeting cytochrome C oxidase subunit 4 (COX4) inhibits growth and induces apoptosis in medullary thyroid cancer cells. Endocrine Society 100th Annual Meeting, Chicago, IL, 2018.

254. Gomes-Lima C, Chittimoju S, Wehbeh L, Jat SK, Pagadala P, Jhavar S, Al-Jundi MN, Zeymo A, Mete M, Klubo-Gwiezdzinska J, Van Nostrand D, Jonklaas J, Wartofsky L, Burman KD. Radioiodine treatment of metastatic thyroid cancer: progression free survival is similar for patients with distant metastases prepared with either recombinant human TSH or with thyroid hormone withdrawal. Endocrine Society 100th Annual Meeting, Chicago, IL, 2018.
255. Lima CJ, Wu D, Turner D, Burman K, Van Nostrand D. Enhancing Techniques for Radioiodine Imaging of Differentiated Thyroid Cancer. *Journal of Nuclear Medicine*. 2018 May 1;59(supplement 1):1193-. SNMMI 2018 Annual Meeting, Philadelphia, PA.
256. Wu D, Ylli D, Lima CJ, Lee W, Burman K, Wartofsky L, Van Nostrand D. New use for an old isotope. *Journal of Nuclear Medicine*. 2018 May 1;59(supplement 1):1338-. SNMMI 2018 Annual Meeting, Philadelphia, PA.
257. Wu D, Heimlich L, Burman K, Wartofsky L, Van Nostrand D. The diagnostic value of 124I PET compared to 131I imaging in differentiated thyroid cancer: systematic review and metaanalysis. *Journal of Nuclear Medicine*. 2018 May 1;59(supplement 1):1334-.
258. Wu D, Kulkarni K, Garcia C, Burman K, Wartofsky L, Van Nostrand D. Optimal time for 124I PET/CT imaging in metastatic differentiated thyroid cancer. *Journal of Nuclear Medicine*. 2018 May 1;59(supplement 1):240-.
259. Wu D, Khorjekar G, Kharazi P, Moreau S, Kulkarni K, Burman K, Wartofsky L, Van Nostrand D. Poor compliance for continuous sialogogues in patient-reported surveys. *Journal of Nuclear Medicine*. 2018 May 1;59(supplement 1):1619-.
260. Shobab L, Gomes-Lima C, Jonklaas J, Wartofsky L, Zeymo A, Burman KD. Clinical, Pathological and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer. 88th Annual Meeting of the American Thyroid Association, Washington, DC, 2018.
261. Shobab L, Patel A, Costello J, Mendonca-Torres MF, Jensen K, Burman KD, Wartofsky L, Vasko V. Sex-specific expression of the histone lysine-specific demethylases in normal thyroid and thyroid cancer. 88th Annual Meeting of the American Thyroid Association, Washington, DC, 2018.
262. Wu D, Bloom G, Burman KD, Wartofsky L, Van Nostrand D. Nationwide survey on the changes in release of I-131 therapy patients after the implementation of the 2011 NRC regulatory policy. 88th Annual Meeting of the American Thyroid Association, Washington, DC, 2018.
263. Patel A, Costello J, Ylli D, Wartofsky L, Burman KD, Vasko V, Jensen K. Targeted nextgeneration-sequencing for analysis of oncogenic mutations in medullary thyroid cancers. 88th Annual Meeting of the American Thyroid Association, Washington, DC, 2018.
264. Ylli D, Jensen K, Costello J, Patel A, Hoperia V, Wartofsky L, Burman KD, Vasko V. Viralinducible cells fusion affects differentiation and chemokine expression in thyroid cancer cells. 88th Annual Meeting of the American Thyroid Association, Washington, DC, 2018.

Articles / Publications

1. Burman KD, Cunningham EJ, Klachko DM, Burns TW. Successful Treatment of Insulin Resistance with Dealinated Pork Insulin. *Missouri Medicine* 363-366, June 1973.
2. Burman KD, Cunningham EF, Klachko DM, Bassoui WE, Burns TW. Factitious Hypoglycemia. *American Journal of the Medical Sciences* 266:23-32, 1973.
3. Burman KD, Broughton RE, Pflaum WK, Wartofsky L. Deiodination of ¹³¹I Labeled Thyroxine in the Fetal Rat. *Proceedings Society Experimental Biology and Medicine* 143:1000-1007, 1973.
4. Burman KD, Warkel R, Wartofsky L. Solitary Autonomous Thyroid Nodules that Become "Cold." *D.C. Annals of medicine* 42:541-544, 1973.
5. Burman KD, Johnson MS, Earll JM, Wartofsky L. Clinical Observations on the Solitary Autonomous Thyroid Nodule. *Achieves Internal Medicine* 134:915-919, 1974.
6. Luzecky MH, Burman KD, Schulttz ER. The Syndrome of Inappropriate Secretion of Antidiuretic Hormone Due to Amitriptylene. *Southern Medical Journal* 67:495-497, 1974.
7. Burman, KD, Solitary Autonomous Thyroid Nodules. *Postgraduate Medicine* 56:70-74, 1974.
8. Burman KD, Adler RA, Wartofsky L. Hemiogenesis of the Thyroid Gland. *American Journal of Medicine* 58:143-146, 1975.
9. Burman KD. What's New for Diabetes. *Medical time* 103:123-138, 1975.
10. Burman KD, Wright FD, Earll JM, Wartofsky L. Evaluation of a Rapid and Simple Technique for the Radioimmunoassay of Triiodothyronine. *J Nucl Med* 16:662-665, 1975.
11. Burman KD, Dimond RC, Noel GN, Earll JM, Frantz AG, Wartofsky L. Klinefelter's Syndrome: Examination of Thyroid Function and TSH and PRL Responses to Thyrotropin Releasing Hormone Prior to and After Testosterone Administration. *J Clin Endocrinol Metab* 41:1161-1166, 1975.
12. Burman KD, Yeager H, Briggs W, Wartofsky L. Resin Hemoperfusion: A Potential New Treatment for Thyroid Storm. *Thyroid Research*, 1975. *Excerpta Medica*, Amsterdam, 437-440, 1976.
13. Burman KD, Dimond RC, Earll JM, Wright FD, Wartofsky L. Sensitivity to Lithium in Treated Graves' Disease: Effects on T3, T4, and Reverse T3. *J Clin Endocrinol Metab* 43:606-613, 1976.
14. Burman KD, Yeager H, Briggs E, Wartofsky L. Resin Hemoperfusion: A Method of Removing Circulating Hormones. *J Clin Endocrinol Metab* 42:70-78, 1976.
15. Burman KD, Monchik J, Earll JM, Wartofsky L. Total and Ionized Calcium and Parathyroid Hormone in Hyperthyroidism. *Ann Int Med* 84:668-671, 1976.
16. Burman KD, Read J, Dimond RC, Strum D, Wright FD, Patow W, Earll JM, Wartofsky L. Thyroid Hormone Parameters in Human Amniotic Fluid and in Cord and Maternal Serum L

- Measurements of 3, 3'-L-triiodothyronine (Reverse T3), 3,3'-L-diiiodothyronine (3,3'-T2), 3,5,3'-triiodothyronine (T3), Thyroxine (T4), Dialyzable T3 and T4, Thyroxine Binding Globulin (TBG), and Total Iodine. *J Clin Endocrinol Metab* 43:1351-1359, 1976.
16. Wartofsky L, Burman KD, Dimond RC, Noel GL, Frantz AG, Earll JM. Studies on the Nature of Thyroidal Suppression During Acute Falciparum Malaria: Integrity of Pituitary Response to TRH and Alterations in the Conversion of Thyroxine to 3, 3',5'-triiodothyronine (T3) and 3,3',5-triiodothyronine (Reverse T3). *J Clin Endocrinol Metab* 44:85-90, 1977.
 17. Burman KD, Dimond RC, Wright FD, Earll JM, Bruton J, Wartofsky L. A Radioimmunoassay for Reverse T3: Assessment of Thyroid Gland Content and Serum Measurement in Conditions Normal and Altered Thyroidal Economy and Following Administration of TRH and TSH. *J Clin Endocrinol Metab* 44:660-672, 1977.
 18. Burman KD, Strum D, Dimond RC, Djuh YY, Wright FD, Earll JM, Wartofsky L. A Radioimmunoassay for 3,3'-L-Diiodothyronine (3,3'T2). *J Clin Endocrinol Metab* 45:339-352, 1977.
 19. Burman KD, Vigersky RA, Loriaux DL, Strum D, Djuh YY, Wright FD, Wartofsky L. Investigation Concerning Thyroxine Deiodinative Pathways in Patients with Anorexia Nervosa. Aven Press, Anorexia Nervosa, ed. Vigersky, RA, 255-261, 1977.
 20. Thrall JH, Burman KD, Gillin MT, Corcoran RJ, Johnson MC, Wartofsky L. Solitary Autonomous Thyroid Nodules: comparison of Fluorescent and Perchnetate Imaging. *J Nucl Med* 18:1064-1068, 1977.
 21. Burman KD, Lukes Y, Wright FD, Wartofsky L. Reduction in Hepatic T3 Binding Capacity Induced by Fasting. *Endocrinology* 101:1331-1334, 1977.
 22. Thrall JH, Burman KD, Wartofsky L, Corcoran RJ, Johnson MC, Gillin MT. Discordant Imaging of a Thyroid Nodule with ¹³⁰I and Fluorescent Scans, *Radiology* 128:705-706, 1978.
 23. Smallridge RC, Wartofsky L, Desjardins RE, Burman KD. Reverse Production Rates in Thyrotoxic, Euthyroid, and Hypothyroid Subjects. *J Clin Endocrinol Metab* 47:345-349, 1978.
 24. Smallridge RC, Wartofsky L, Chopra IJ, Solomon DIH, Dimond RC, Marinelli PV, Broughton RE, Earll JM, Burman KD. Neonatal Thyrotoxicosis: Relationship LATS-Protector to Alteration in Serum T4, T3, Reverse T3, and 3, 3'T2 Concentrations. *J Pediatrics* 93:118-120, 1978.
 25. Burman KD, Djuh YY, Dimond RC, Wartofsky L. Failure of 3, 3'T2 Administration to Alter TSH and Prolactin Responses to TRH Stimulation. *Metabolism* 27:677-683, 1978.
 26. Smallridge RC, Wartofsky L, Desjardins RE, Burman KD. Metabolic Clearance and Production Rates of 3, 3'5-Triiodothyronine in Hyperthyroid, Euthyroid, and Hypothyroid Subjects. *J Clin Endocrinol Metab* 47:345-349, 1978
 27. Corrigan DF, Wartofsky L, Dimond RC, Schaaf M, Rogers JC, Wright FD, Burman KD. Parameters of Thyroid Function in Patient With Active Acromegaly. *Metabolism* 27:209-216, 1978.
 28. Burman KD, Wright FD, Smallridge RC, Green BJ, Georges LP, Wartofsky L. A

- Radioimmunoassay for 3',5'-diiodothyronine. *J Clin Endocrinol Metab* 47:1059-1064, 1978.
29. Glass AR, Mellitt R, Burman KD, Wartofsky L, Swerdloff RS. Serum T3 in Undernourished Rats: Dependence on Dietary Composition Rather than Total Calorie or Protein Intake. *Endocrinology* 102:1925-1928, 1978.
 30. Burman KD, Harvey GS, O'Brian JT, Georges LP, Bruton J, Wright FD, Dimond RC, Wartofsky L. Glucose Modulation of Peripheral Thyroid Hormone Metabolism. *Metabolism* 28:291-299, 1979.
 31. Smallridge RC, Wartofsky L, Green BJ, Miller FC, Burman KD. 3'L-monoiodothyronine (3'T1): Development of a Radioimmunoassay and Demonstration of In Vivo Conversion From 3',5'-diiodothyronine. *J Clin Endocrinol Metab* 48:32-36, 1979.
 32. Burman KD, Dinterman R, Wartofsky L, Kesler P, Wannemacher RW. The Effect of T3 and Reverse T3 Administration on Muscle Protein Catabolism during Fasting as Measured by 3 Methylhistidine Excretion. *Metabolism* 28:805-813, 1979.
 33. Burman KD, Smallridge RC, Osburne R, Dimond RC, Whorton NE, Kesler P, Wartofsky L. Nature of Suppressed TSH Secretion during Undernutrition: Effect of Fasting and Refeeding on TSH Responses to Prolonged TRH Infusions. *Metabolism* 29:46-52, 1980.
 34. Burman KD, Smallridge RC, Jones L, Ramos EA, O'Brian JT, Wright FD, Wartofsky L. Glucagon Kinetics in Fasting: A Metabolic Event Associated with Physiologic Alterations in Serum T3. *J Clin Endocrinol Metab* 51:1158-1165, 1980.
 35. Becker RA, Wilmore DW, Godwin CW, Zitzka CA, Wartofsky L, Burman KD, Mason AD, Pruitt BA. Free T4, Free T3 and Reverse T3 in Critically Ill, Thermally Injured Patients. *J of Trauma* 20:713-721, 1980.
 36. Burman KD, Latham KR, Djuh YY, Smallridge RC, Tseng YL, Lukes YG, Maunder R, Wartofsky L. Solubilized Nuclear Thyroid Hormone Receptors in Circulating Human Mononuclear Cells: Evidence for Increased Maximum Binding Capacities in Fasted Obese Subjects. *J Clin Endocrinol Metab* 51:106, 1980.
 37. O'Brian JT, Bybee DE, Burman KD, Osburne RC, Ksiazek MR, Wartofsky L, Georges LP. Thyroid Hormone Homeostasis in States of Relative Calorie Deprivation. *Metabolism* 29:721, 1980.
 38. Pangaro L, Burman KD, Wartofsky L, Cahnmann HJ, Smallridge RC, O'Brian JT, Wright FD, Latham KR. Radioimmunoassay for 3, 5'-diiodothyronine (3,5T2) and Evidence for Dependence on Conversion From T3. *J Clin Endocrinol Metab* 6:1075-1081, 1980.
 39. Boehm TM, Burman KD, Barnes S, Wartofsky L. Lithium and Iodide Combination Treatment for Thyrotoxicosis. *Acta Endocrinologica* 94:174-183, 1980.
 40. Wray HL, Burman KD, Smallridge RC, Alford JP, Butler VM, Wright FD, Wartofsky L. Effect of T3 and Reverse T3 Administration on Serum Tri-Di- and Monoiodothyronines and Plasma Cyclic Nucleotide in Sheep. *Endocrinology* 107:1081, 1980.
 41. Thompson P, Burman KD, Lukes YG, McNeil JS, Jackson BD, Latham KR, Wartofsky L. Uremia Decreases Nuclear T3 Receptors in Rats. *Endocrinology* 107:1081, 1980.

42. Boehm TM, McLain J, Burman KD, deShazo R, Wartofsky L. Iodine Treatment of Iodine-induced Thyrotoxicosis. *J Endocrinol Invest* 3: 419-424, 1980.
43. Burman KD, Lukes YG, Latham KR, Wartofsky L. Iodate and 8-anilino-1-naphthalene Sulfonic Acid Block Receptor Binding of T₃ in Rat Liver. *Hormone and Metabolic Research* 12:685-687, 1980.
44. Maxon HR, Burman KD, Premachandra BN. Euthyroid Familial Hyperthyroxinemia [Letter]. *N Eng J Med* 302:1263, 1980.
45. Wartofsky L, Latham KR, Djuh YY, Burman KD. Alterations in T₃ and T₄ Receptor Binding in Fasting and Diabetes Mellitus. *Life Sci* 28:1683-1691, 1981.
46. Burman KD, Bongiovanni R, Garis RK, Wartofsky L, Boehm T. Measurement of Serum T₄ Levels by High Performance Liquid Chromatography. *J Clin Endocrinol Metab* 53:909, 1981.
47. Bongiovanni R, Burman KD, Garis RK, Boehm T. HPLC Measurement of Dansyl-thyroxine in Femtomole Range. *J Liquid Chromatography* 4(5):813-24, 1981.
48. DeRuter H, Burman KD, Wartofsky L, Taylor S. Effects of Thyroid Hormone on the Insulin Receptor in Rat Liver Membranes. *Endocrinology* 110, 1981.
49. Maxon HR, Burman KD, Premachandra BN, Chen IW, Burger A, Levy P, Georges LP. Familial Elevations of Total and Free Thyroxine in Healthy, Euthyroid Subjects Without Detectable Binding Protein Abnormalities. *Acta Endocrinol* 100:224
50. Smallridge RC, Wartofsky L, Burman KD. Thyroid Carcinoma and Hodgkin's Disease. *Annals Int Med* 94:412-413, 1981.
51. Burman KD, Lukes YG, Latham KR, Smallridge RC, Wartofsky L. The Effect of Dexamethasone, Diet Control and Hyperglycemia on Murine Hepatic T₃ Receptors. *Life Sciences* 28:1701-1712, 1981.
52. Wartofsky L, Latham KR, Djuh YY, Burman KD. Human T₃ Receptors in Fasting and Diabetes Mellitus. *Life Sciences* 28:1683-1691, 1981.
53. Smallridge RC, Smith CE, Wright FD, Wartofsky L, Burman KD. Metabolic Clearance Rate and Production Rate of 3,5-T₂ in Hyper- and Hypothyroidism. *J Clin Endocrinol Metab* 52:722-730, 1981.
54. Smallridge RC, Burman KD, Ward KE, Dimond RC, Wright KR, Wartofsky L. 3',5'-diiodothyronine to 3'-monoiodothyronine Conversion in the Rat: Enzyme Characteristics and Evidence for Two Distinct 5'-Deiodinases. *Endocrinology* 108:2336, 1981.
55. Glass AR, Burman KD, Dahms WT, Boehm TM. Endocrine Function in Human Obesity. *Metabolism* 30:89-104, 1981.
56. Zwillich C, Martin B, Rose E, Charles A, Hofeldt F, Burman KD. Lack of Effects of Dense Beta Sympathetic Blockade on Metabolic Rate and Respiratory Resource to Carbohydrate Feeding. *Metabolism* 30:451, 1981.

57. Wartofsky L and Burman KD. Alterations in Thyroid Function in Patients with Systemic Illness: The "Euthyroid Sick Syndrome." *Endocrin Rev* 3:164-217, 1982.
58. Swartz M, Burman KD, Salen G. Cerebroretinoid Xanthomatosis: A Potentially Treatable Lethal Disease Presenting With Cataracts. *Amer J Medical Sciences* 283(3):147-152, 1982.
59. Smallridge RC, Wartofsky L, Burman KD. The Effect of Experimental Hyper- and Hypothyroidism on 5'-monodeiodination of Reverse T3 and 3',5'-diiodothyronine by Rat Liver and Kidney. *Endocrinology* 11:2066-2069, 1982.
60. Thompson PT, Burman KD, Wartofsky. Iodothyronines Levels in Human Cerebrospinal Fluid. *J Clin Endocrinol Metab* 54(3):653-655, 1982.
61. Burman KD, Boehm T, Bongiovanni R. Compendium of the Joint FDA/USP Workshop on Drug and Reference Standards, for Insulins, Somatropins, and Thyroid Axis Drugs. NIH publications, 1982.
62. Borst GC, Premachandra BN, Burman KD, Osburne RC. Euthyroid Familial Hyperthyroxenemia Due to an Abnormal Thyroid Hormone Binding Protein. *Amer J Med* 73:293-289, 1982.
63. Burman KD. "Hanging From the Masthead": Reflection on Authorship. *Ann Int Med* 97:602-605, 1982.
64. Smallridge RC, Glass AR, Wartofsky L, Ward KE, Latham KR, Burman KD. Investigations into the Etiology of Elevated Serum T3 Levels in Protein Malnourished Rats. *Metabolism* 31:538, 1982.
65. Borst GC, Eil C, Burman KD. Euthyroid Hyperthyroxinemia. *Ann Intern Med* 98:66-78.
66. Borst GC, Osburne RC, O'Brien JT, Georges LP, Burman KD. Fasting Decreases TSH Responsiveness: A Potential Cause of Misinterpretation of Thyroid Function Tests in the Critically Ill. *J Clin Endocrinol Metab* 57:380-383, 1983.
67. Baker Jr JR., Lukes YG, Smallridge RC, Berger M, Burman KD. Partial Characterization and Clinical Correlation of TSH Displaceable Guinea Pig Membrane Binding Human Immunoglobulins as Evaluated by Direct Enzyme Immunoassay. *J Clinical Investigation* 72:1487-1497, 1983.
68. Chernow B, Burman KD, Johnson DL, McGuire RA, O'Brien JT, Wartofsky L, Georges LP. T3 May Be A Better Agent Than T4 in the Critically Ill Hypothyroid Patient: Evaluation of Transport Across the Blood-Brain Barrier in a Primate Model. *Crit Care Med* 11:99-104, 1983.
69. Osburne RC, Myers EA, Rodbard D, Burman KD, Georges LP, O'Brien JT. Adaptation to Hypocaloric Feeding: Physiologic Significance of the Fall in Serum T3 as Measured by the Pulse Wave Arrival Time (Qkd). *Metabolism* 32:9-13, 1983.
70. Wortsman J, Premachandra BN, Williams K, Burman KD, Hay ID, Davis PJ. Familial Resistance to Thyroid Hormone Associated with Decreased Transport across the Plasma Membrane. *Ann Int Med* 98:904-909, 1983.

71. Burman KD, Smallridge RC, Burge JR, Carlson D, Wartofsky L. Iodate Restores the Fasting Induced Decrement in TSH Secretion. *J Clin Endocrinol Metab* 57:597-602, 1983.
72. DeRuyter H, Burman KD, Wartofsky L, Smallridge RC. Thyrotropin Secretion in Starved Rats is Enhanced by Somatostatin Antiserum. *Hormone and Metabolic Research* 16:92-96, 1984.
73. Wartofsky L and Burman KD. Effects of Drugs on Peripheral Thyroxine Metabolism. *Horm Metab Res Suppl* 1984;14:105-108, 1984.
74. Glass AR, Vigersky RA, Rajatanavin R, Smallridge RC, Wartofsky L, Burman KD. Low Serum Thyroxine and High Serum Triiodothyronine in Nephrotic Rats: Etiology and Implications for Bioavailability of Protein-Bound Hormone. *Endocrinology* 114:1745-1753, 1984.
75. Margolick JB, Hsu S-M, Volkman DJ, Burman KD, Fauci AS. Immunohistochemical Characterization of Intrathyroid Lymphocytes in Graves' Disease: Interstitial and Intraepithelial Populations. *Amer J Med* 76:815-821, 1984.
76. Baker Jr JR, Lukes YG, Burman KD. Production, Isolation and Characterization of Rabbit Anti-idiotypic Antibodies Directed against Human Antithyrotrophin Receptor Antibodies. *J of Clin Invest* 74:488-495, 1984.
77. Carlson DE and Burman KD. The Effectiveness of Carefully Monitored Modified Fast as Adjuvant Therapy for Exogenous Obesity in Active Duty Personnel. *Military Medicine* 149:669-671, 1984.
78. McDermott MT, Burman KD, Hofeldt FD, Kidd GS. Lithium Associated Thyrotoxicosis. *Amer J Med* 80:1245-1248, 1984.
79. Clark IJ, Wright PJ, Chamley WA, Burman KD. Differences in the Reproductive Endocrine Status of Ewes in the Early Post-Partum Period and during Seasonal Anoestrus. *J Reprod Fertil* 70:591-597, 1984.
80. Smallridge RC, Whorton NE, Burman KD, Ferguson EW. Effects of Exercise and Physical Fitness on the Pituitary-Thyroid Axis and on Prolactin Secretion in Male Runners. *Metabolism* 34:949, 1985.
81. Burman KD, Lukes YG, Wartofsky L, Djuh Y-Y, Baker Jr JR. Preparation of Biotinylated Receptor Purified Graves' IgG: A Simple Technique Allowing Direct Functional Assessment of TSH Receptor Antibody Binding to Membranes. In *Autoimmunity and the Thyroid*, ed. Walfish PG, Wall JR, Volpe R. Academic Press, Montreal, 1985.
82. Zaloga GP, Chernow B, Smallridge RC, Zajtchuk R, Hall-Boyer K, Hargraves R, Lake CR, Burman KD. A Longitudinal Evaluation of Thyroid Function in Critically Ill Surgical Patients. *Ann Surg* 201:456-464, 1985.
83. Smallridge RC, Chernow B, Snyder R, Zaloga GP, Burman KD. Angiotensin-Converting Enzyme: A Potential Marker of Tissue Hypothyroidism in Critical Illness. *Arch Intern Med* 145(10):1829-32, 1985.
84. Raines KB, Baker Jr JR., Lukes YG, Burman KD. Anti-Thyrotropin Antibodies in the Sera of Graves' Disease. *J of Clin Endocrinol Metab* 61:217-222, 1985.

85. Zucker A, Chernow B, Fields AI, Hung W, Burman KD. Evaluation of Thyroid Function in Critically Ill Children. *J Pediatr* 107:552-554, 1985.
86. Tseng Y-C, Burman KD, Baker JR, Wartofsky L. A Rapid and Sensitive Enzyme - Linked Immunoassay (EIA) for Human Thyrotropin (TSH). *Clin Chem* 31:1131, 1985.
87. Hennessey JV, Burman KD, Wartofsky L. The Equivalency of Two L-Thyroxine Preparations. *Annals Int Medicine* 6:770-773, 1985.
88. Hay ID, Gorman CA, Burman KD, Jian N-S. Stereospecific Determination and In Vivo Monodeiodination of Thyroxine Enantiomers in Euthyroid Man. *Metabolism* 34:266-271, 1985.
89. Weetman AP, Volkman DJ, Burman KD, Gerrard TL, Fauci AS. The In Vitro Regulation of Human Thyrocyte HLA-DR Antigen Expression. *J Clin Endocrinol Metab* 61:817-24, 1985.
90. Weetman AP, Volkman DJ, Burman KD, Fauci AS. Activation, Proliferation and Differentiation of Circulating B Cells in Autoimmune Thyroid Disease. *J Immunology* 135:3138-3143, 1985.
91. Raines KB, Baker Jr JR., Lukes YG, Wartofsky L, Burman KD. Antithyrotropin Antibodies in the Sera of Graves' Disease Patients. *Clin Endocrinol Metab* 61:217, 1985.
92. Hennessey JV, Burman KD, Wartofsky L. Thyroxine Bioequivalency. *Ann Intern Med* 103:647, 1985 (Letter).
93. Burman KD, Ferguson EW, Djuh YY, Wartofsky L, Latham K. Beta Receptors in Peripheral Mononuclear Cells Increase Acutely during Exercise. *Acta Endocrinol* 109:563-568, 1985.
94. Burman KD and Baker Jr JR. Immune Mechanisms in Graves' Disease. *Endocrine Rev* 6:183-232, 1985.
95. Graham GD and Burman KD. Radioiodine Treatment of Graves' Disease: An Assessment of its Potential Risks. *Ann Intern Med* 105:901-905, 1986.
96. Burman KD. Graves' Disease: Studies Concerning TSH-receptor Antibody Formation and Action. *Clinical Research* 34:432-437, 1986.
97. Hennessey JV, Evaul JE, Tseng YC, Burman KD, Wartofsky L. L-thyroxine Dosage: A Re-evaluation of Therapy with Contemporary Preparations. *Ann Int Med* 105:11-15, 1986.
98. Reed HL, Burman KD, Shakir KM, O'Brian JT. Alterations in the Hypothalamic-Pituitary-Thyroid Axis after Prolonged Residence in Antarctica. *Clinical Endocrinol* 25:55-65, 1986.
99. Sack J, Baker JR Jr., Weetman AP, Wartofsky L, Burman KD. The Role of Antibody-Dependent Cytotoxicity and Natural Killer Cells in Hashimoto's Disease. In *Frontiers in Thyroidology*, vol. 2. G. Medeiros-Neto and E. Gaitan, eds. Plenum Publishing Co, 1986.
100. Weetman AP, Volkman DJ, Burman KD, Margolick JB, Petrick P, Weintraub BD, Fauci AS. The Production and Characterization of Thyroid-Derived T-Cell Lines in Graves' Disease and Hashimoto's Thyroiditis. *Clin Immunology Immunopathol* 39:139-50, 1986.

101. Hennessey JV, Evaul JE, Tseng YC, Burman KD, Wartofsky L. Re-evaluation of L-thyroxine Dose. *Ann Intern Med* 105:797-798, 1986 (Letter).
102. Weetman AP, Smallridge R, Hayslip C, Burman KD. Multiple Autoantigenic Determinants in Thyroid Autoimmunity. In "Thyroid Autoimmunity: Memories and Perspectives." Plenum Publishing Corp, 1986.
103. Burman KD and Baker Jr JR. Autoimmune Graves' Disease. *The Bridge Newsletter*, 1986.
104. Weetman AP, Nutman TB, Burman KD, Baker JR, Fauci AS Volkman DJ. Heterogeneity of Thyroid Autoantigens Identified by Immunoblotting. *Clin Immunol and Immunopathology* 43:333-342, 1987.
105. Weetman AP, Smallridge RC, Nutman TB, Burman KD. Persistent Thyroid Autoimmunity after Subacute Thyroiditis. *J Clin and Lab Immuno* 23:1-6, 1987.
106. Butkus NE, Burman KD, Smallridge RC. Angiotensin-Converting Enzyme Activity Decreases During Fasting. *Horm Metab Res* 19:76-7, 1987.
107. Solomon BL, Evaul JE, Burman KD, Wartofsky L. Remission Rates with Antithyroid Drug Therapy: Continuing Influence of Iodine Therapy. *Ann Intern Med* 107:510-512, 1987.
108. Ahmann A, Baker JR, Jr., Weetman AP, Wartofsky L, Nutman TB, Burman KD. Antibodies to Porcine Eye Muscle in Patients with Graves' Ophthalmopathy: Identification of Serum Immunoglobulins Directed against Unique Determinants by Immunoblotting and Enzyme-linked Immunosorbent Assay. *J Clin Endocrinol Metab* 64: 454-460, 1987.
109. Weetman AP, Nutman TB, Baker JR, Jr., Burman KD. Demonstration by Immunoblotting of Heterogeneity in the Autoantibody Response Directed against Fat Cells in Graves' Disease. *FEBS Letters* 211:69-72, 1987.
110. Burman KD. "Hypothyroidism," *Conn's Current Theory*, ed. Rakel R, W.B. Saunders, Co., p. 521, 1987.
111. Tseng YC, Burman KD, Baker Jr JR., D'Avis J, Wartofsky L. Intrinsic Abnormality of Thyroid Cells from a Patient with a Broddingnagian Goiter. *J Endocrinological Invest* 10:517-522, 1987.
112. Ahmann AJ and Burman KD. The Role of T Lymphocytes in Autoimmune Thyroid Disease. *Endocrinology and Metabolism Clinics of North America*, 16:287-327, 1987.
113. Burman KD, Djuh YY, LaRocca RV, Nunes ME, D'Avis JC, Nicholson DE, Wartofsky L. C-myc Expression in the Thyroid I: Normal, Adenomatous, and Cancerous Thyroid Tissue. *Horm Metab Res (Suppl)* 17:63-65, 1987.
114. Nunes ME, Djuh YY, LaRocca RV, Nicholson DE, Baker JR Jr., Wartofsky L, D'Avis JC, Burman KD. C-myc Expression in the Thyroid II: Thyrocytes and Peripheral and Intrathyroidal Lymphocytes from Patients with Autoimmune Thyroid Disease. *Horm Metab Res (Suppl)* 17:66-69, 1987.
115. Sack J, Baker JR Jr., Weetman AP, Wartofsky L, Burman KD. Thyrocyte Specific Killer Cell Activity is Decreased in Patients with Thyroid Carcinoma. *Cancer* 59:1914-1917, 1987.

116. Burman KD, Smallridge RC, Burge JR, O'Brian JT, Wartofsky L. Iodide Administration Enhances Thyrotropin Responsiveness to Thyrotropin-Releasing Hormone during Fasting: Evidence for Normal Pituitary Feedback Regulation. *Clin Endocrinol* 26:9-15, 1987.
117. Dolev E, Deuster PA, Solomon B, Trostmann V, Burman KD. Alterations in Magnesium and Zinc Metabolism in Thyroid Disease. *Metabolism* 37:61-67, 1988.
118. Baker JR Jr., Saunders NB, Kaufersch W, Burman KD. The Development of Human Monoclonal Antibodies from Graves' Disease Patients which Demonstrate the Ability to Inhibit TSH-mediated Production of Cyclic-Adenosine Monophosphate in Thyrocytes. *J Immunology* 140:2593-2599, 1988.
119. Nuovo JA, Baker JR Jr., Wartofsky L, Lukes YG, Burman KD. Autoantibodies to Insulin are Present in the Sera of Patients with Autoimmune Thyroid Disease. *Diabetes* 37:317-320, 1988.
120. Wortsman J, McConnachie P, Baker JR Jr., Burman KD. Immunoglobulins that Cause Thyrocyte Proliferation from a Patient with Graves' Disease and an Enlarged Thymus. *Am J Med* 85:117-21, 1988.
121. Margolick JB, Weetman AP, Burman KD. Immunohistochemical Analysis of Intrathyroid Lymphocytes in Graves' Disease: Evidence of Activated T Cells and Interferon-Gamma. *Clin Immunol and Immunopathology* 47:208-218, 1988.
122. Kaufersch W, Baker JR Jr., Burman KD, Ahmann AJ, D'Avis JC, Waldmann TA. Immunoglobulin and T Cell Gene Rearrangements Indicate that the Immune Response in Autoimmune Thyroid Disease (AITD) is Polyclonal. *J Clin Endocrinol Metab* 66:958-963, 1988.
123. Baker JR, Saunders NA, Tseng YC, Wartofsky L, Burman KD. Seronegative Hashimoto's Thyroiditis with Thyroid Autoantibody Production Localized to the Thyroid. *Ann Intern Med* 108:26-30, 1988.
124. Reed HL, Ferreiro JA, Shakir KMM, Burman KD, O'Brian JT. Pituitary and Peripheral Hormone Responses to T3 Administration during Antarctic Residence. *Amer J Physiology* 254:E733-739, 1988.
125. Burman KD. "Hypothyroidism," in *Current Therapy in Allergy, Immunology, and Rheumatology*, eds. Fauci AC, Lichtenstein LM, B.C. Decker, Inc., 1988.
126. Hayslip CC, Baker JR Jr., Wartofsky L, Klein TA, Opsahl MS, Burman KD. Natural Killer Cell Activity and Serum Autoantibodies in Women with Postpartum Thyroiditis. *J Clin Endocrinol Metab* 66:1089-93, 1988.
127. Burman KD, Baker JR, Tseng YC, Saunders N, Solomon B, Wartofsky L. Eponyms (Letter). *Ann Intern Med* 108:635, 1988.
128. Premachandra BN, Burns TW, Bregant R, Williams IK, Burman KD. Persistence of Low Serum Thyroid Hormone Levels in a Graves' Disease Patient Receiving

129. Tseng YC, Burman KD, Schaudies RP, Ahmann A, D'Avis J, Geelhoed GW, Wartofsky L. Effects of Epidermal Growth Factor on Thyroglobulin and Adenosine 3,5'-Monophosphate Production by Cultured Human Thyrocytes. *J Clin Endocrinol Metab* 69:771-775, 1989.
130. Tseng YC, Sellitti DF, Ahmann AJ, Burman KD, D'Avis JC, Wartofsky L. Thyrotropin Modulates Receptors for Atrial Natriuretic Factor on Intact Human Thyroid Cells. *Amer J Med Sci* 298:15-19, 1989.
131. Kaulfersch W, Baker JR Jr., Burman KD, Fiocchi C, Ahmann AJ, D'Avis JC, Waldmann TA. Molecular Genetic Detection of Polyclonal Immune Response in Autoimmune Thyroiditis and Inflammatory Bowel Diseases. *Monatsschr Kinderheilkd* 137:610-615, 1989.
132. Sack, J, Zilberstein D, Barile MF, Wartofsky L, Lukes YG, Baker JR Jr, Burman KD. Binding of Thyrotropin to Selected Mycoplasma Species: Detection of Serum antibodies against a Specific Mycoplasma Membrane Antigen in Patients with Auto-immune Thyroid Disease. *J Endocrinol Invest* 12:77-86, 1989.
133. Burman KD, Anderson JH, Wartofsky L, Mong DP, Jelinek JJ. Management of Patients with Thyroid Carcinoma: Application of Thallium-201 Scintigraphy and Magnetic Resonance Imaging. *J Nucl Med* 31: 1958-64,1990.
134. Reed HL, Brice D, Shakir KM, Burman KD, D'Alesandro M, O'Brian JT. Decreased Free Fraction of Thyroid Hormones after Prolonged Antarctic Residence. *J Appl Physiol* 69:1467-72, 1990.
135. Tseng YCL, Lahiri S, Sellitti DF, Burman KD, D'Avis JC, Wartofsky L. Characterization by Affinity Cross-linking of a Receptor for Atrial Natriuretic Peptide in Cultured Human Thyroid Cells Associated with Reductions in Both Adenosine 3'5'-monophosphate Production and Thyroglobulin Secretion. *J Clin Endocrinol Metab* 70:528-533, 1990.
136. Troumbley PF, Burman KD, Rinke WJ, Lenz ER. A Comparison of the Health Risk, Health Status, Self-Motivation, Psychological Symptomatic Distress, and Physical Fitness of Overweight and Normal Weight Soldiers. *Military Med* 155:424-429, 1990.
137. Norby EH, Neutze J, Van Nostrand D, Burman KD, Warren RW. Nasal Radioiodine Activity: A Prospective Study of Frequency, Intensity and Pattern. *J Nucl Med* 31:52-54, 1990.
138. Burman KD. "Hashimoto's Thyroiditis" in *Current Therapy in Internal Medicine*, ed. Jerome Kassirei, 1990.
139. Reed HL, Silverman ED, Shakir KMM, Dons R, Burman KD, O'Brian JT. Changes in Serum Triiodothyronine Kinetics after Prolonged Antarctic Residence: The Polar T3 Syndrome. *J Clin Endocrinol Metab* 70:965-974, 1990.
140. Reed HL, Brice D, Shakir KMM, Burman KD, D'Alesandro MM, O'Brian JT. Decreased Free Fraction of Thyroid Hormones after Prolonged Antarctic Residence. *J Appl Physiology* 69:1467-1472, 1990.
141. Burman KD. Is Long-term Thyroxine Therapy Safe? (Editorial) *Arch Intern Med*, 150:2010-2013, 1990.

142. Smallridge RC, Burman KD, Wartofsky L. Malabsorption of Thyroxine, Calcium, and Vitamin D in a Thyroparathyroidectomized Woman: Efficacy of Therapy with Medium Chain Triglyceride Oil. *Military Med* 155:156-158, 1990.
143. Burman KD. "Thyrotoxicosis," in *Principles and Practices of Endocrinology and Metabolism*, ch. 34, pp. 331-347. K. Becker, ed. J.B. Lippincott, 1990.
144. Burman KD, Anderson JH, Wartofsky L, Mong DP, Jelinek JJ. Management of Patients with Thyroid Carcinoma: Application of Thallium-201 Scintigraphy and Magnetic Resonance Imaging. *J Nucl Med* 31:1958-1964, 1990.
145. Tseng YC, Burman KD, Lahiri S, D'Avis JC, Abdelrahim M, Wartofsky L. Thyrotropin Modulates Receptor-mediated Processing of the Atrial Natriuretic Peptide Receptor Complex in Cultured Thyroid Cells. *J Clin Endocrinol Metab* 72:669-674, 1991.
146. Burman KD. "Immunoassays, Nonradionucleotide" in *Encyclopedia of Human Biology*, pub. Harcourt, Brace, and Jovanovich, and Academic Press, ed. Renate Dulbecco, 4:351-56, 1991.
147. Baker JR, Miller FW, Steinberg AD, Burman KD. Thyroid Stimulating and Thyrotropin Binding Inhibitory Immunoglobulin Activity in Patients with Systemic Lupus Erythematosus having Thyroid Function Abnormalities. *Thyroid* 1:229-234, 1991.
148. Fein HG, Burman KD, Djuh YY, Usala SJ, Bale AE, Weintraub BD, Smallridge RC. Tight Linkage of the Human c-Erb A Beta Gene with the Syndrome of Generalized Hormone Resistance is Present in Multiple Kindreds. *J Endocrinol Invest* 14:219-223, 1991.
149. Francis T, Burch HB, Cai WY, Lukes Y, Peele M, Carr FE, Wartofsky L, Nicholson D, Burman KD. Lymphocytes Express Thyrotropin Receptor Specific Messenger RNA as Detected by the PCR Techniques. *Thyroid* 1:223-228, 1991.
150. Burch HB, Nagy EV, Lukes YG, Cai WY, Wartofsky L, Burman KD. Nucleotide and Amino Acid Homology between the Human Thyrotropin Receptor and the HIV-1 Nef Protein: Identification and Functional Analysis. *Biochem & Biophys Res Communications* 181:498-505, 1991.
151. Burman KD. Treatment of Autoimmune Ophthalmopathy. *The Endocrinologist* 1:102-110, 1991.
152. Humphrey M, Mosca J, Baker JR Jr, Drabick JJ, Carr FE, Burke DS, Wartofsky L, Djuh YY, Burman KD. Absence of Retroviral Sequences in Graves' Disease. *Lancet* 337:17-8, 1991.
153. Humphrey ML and Burman KD. Retrosternal and Intrathoracic Goiter. *The Endocrinologist*. 2:195-201, 1992.
154. Cai WY, Lukes YG, Burch HB, Djuh YY, Carr FE, Wartofsky L, Rhooms P, D'Avis JC, Baker JR Jr., Burman KD. Analysis of Human TSH Receptor Gene and RNA Transcripts in Patients with Thyroid Disorders. *Autoimmunity* 13:43-50, 1992.
155. Haibach H, Burns TW, Carlson HE, Burman KD, Deftos LJ. Multiple Hamartoma Syndrome

- (MHS, Cowden's Disease) Associated with Renal Cell Carcinoma and Primary Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma). *Am J Clin Pathol* 97:705-12, 1992
156. Burman KD, Djuh Y-Y, Nicholson D, Rhooms P, Wartofsky L, Fein HG, Usala SJ, Hao E-H, Bradley WEC, Berard J, Smallridge RC. Generalized Thyroid Hormone Resistance: Identification of an Arginine to Cystine Mutation in Codon 315 of the C-erb A Beta Thyroid Hormone Receptor. *J Endocrinol Invest* 15:573-79, 1992.
 157. Burman KD, Kaplan KA. Autoimmune Ophthalmopathy: Present Concepts Regarding Diagnosis, Analysis and Treatment. *Guthrie Medical J* 61:5-14, 1992.
 158. Jackson S, Tseng Y-C, Lahiri S, Burman KD, Wartofsky L. Receptors for Endothelin in Cultured Human Thyroid Cells and Inhibition by Endothelin of Thyroglobulin Secretion. *J Clin Endocrinol* 75:388-92, 1992.
 159. Nagy EV, Burch HB, Mahoney K, Lukes YG, Morris JC III, Burman KD. Graves' IgG Recognizes Linear Epitopes in the Human Thyrotropin Receptor. *Biochem & Biophys Res Comm* 188:28-33, 1992.
 160. Tseng Y-C, Burman KD, Lahiri S, D'Avis J, Wartofsky L. Thyrotropin Modulation of Epidermal Growth Factor (EGF) Binding to Receptors on Cultured Thyroid Cells. *Thyroid* 2:181-187, 1992.
 161. Nagy E, Burman KD. Enzyme-linked Immunosorbent Assays (ELISA). In press, *Handbook of Hormonal Assay Techniques*, Academic Press, Inc.
 162. Burch HB, Nagy EV, Kain KC, Lanar DE, Carr FE, Wartofsky L, Burman KD. Expression Polymerase Chain Reaction for the In Vitro Synthesis and Epitope Mapping of Autoantigen: Application to the Human Thyrotropin Receptor. *J Immunol Methods* 158:123-30, 1993.
 163. Solomon BL, Wartofsky L, Burman KD. Adjunctive Cholestyramine Therapy for Thyrotoxicosis. *Clinical Endocrinology* 38:39-43, 1993.
 164. Tseng Y-C, Lahiri S, Jackson S, Burman KD, Wartofsky L. Endothelin Binding to Receptors by Human Thyroid Follicular Cells: Effects of Transforming Growth Factor- β and Thyrotropin. *J Clin Endocrinol Metab* 76:156-61, 1993.
 165. Solomon BL, Burman KD. The Prevalence of Fractures in Postmenopausal Women with Thyroid Disease. *Thyroid* 3:17-23, 1993.
 166. Burch HB, Cranston TJ, Anderson JH, Burman KD. Combined Free Thyroxine and Sensitive TSH Testing in a Large Clinical Practice: Comparison with Conventional Thyroid Function Testing. Submitted for publication, 1993.
 167. Burman KD, "Thyroid Hormones," ch. 34, pp. 671-691, in *The Pharmacologic Approach to the Critically Ill Patient*, 2nd edition. Chernow B, Williams and Wilkins (eds.), 1988. Third edition in press, 1993.
 168. Mengistu M, Lukes YG, Nagy EV, Burch HB, Carr FE, Lahiri S, Burman KD. TSH Receptor Gene Expression in Retroocular Fibroblasts. Submitted for publication, 1993.

169. Peele ME, Carr FE, Baker JR Jr, Wartofsky L, Burman KD. TSH Beta Subunit Gene Expression in Human Lymphocytes. *Amer J Med Sci* 305:1-7, 1993.
170. Burch HB, Nagy E, Kain K, Lanar D, Carr FE, Wartofsky L, Burman KD. Expression PCR for the In Vitro Synthesis of Autoantigen: Application to the Human Thyrotropin Receptor. *J Immunol Methods* 158:123-30, 1993.
171. Nagy E, Burch HB, Lukes YG, Kosugi S, Kohn LD, Burman KD. Immunogenicity of a Unique Region of the Human Thyrotropin Receptor. *Journal of Endocrinological Investigation* 16:48593, 1993.
172. Burch HB, Nagy EV, Kain KC, Lanar DE, Carr FE, Wartofsky L, Burman KD. Expression Polymerase Chain Reaction for the In Vitro Synthesis and Epitope Mapping of Autoantigen: Application to the Human Thyrotropin Receptor. *J Immunol Methods* 158:123-30, 1993.
173. Nagy EV, Burch HB, Burman KD. Unidirectional Shift of the Dominant T Cell Epitope in the Human Thyrotropin Receptor in Graves' Disease. Submitted, 1993.
174. Solomon B, Wartofsky L, Burman KD. Management of Differentiated Thyroid Carcinoma: Results of a Survey of American Thyroid Association Members Submitted, 1993.
175. Burch HB, Sellitti D, Barnes SG, Nagy EV, Bahn RS, Burman KD. Identification and Partial Characterization of Proteins Immunologically Related to the Thyrotropin Receptor in Cultured Human Retroocular Fibroblasts. *J Clin Endocrinol Metab* 78: 1384-1391, 1994
176. Lasswell WL, Burman KD. "Thyroid Function Tests and Methods of Imaging the Thyroid Gland." In: McDermott MT (ed), *Endocrinology Secrets*. Philadelphia: Hanley and Belfus, 1994.
177. Duncan WE, Burman KD. Bone densitometry. Precision error is low. *BMJ* 308: 1567, 1994.
178. Loughney MH, Burman KD. "Unusual Forms of Thyrotoxicosis". *Advances in Endocrinology and Metabolism*. Mosby Year Book, Inc., 5:349-392, 1994.
179. Burch H, Solomon BL, Wartofsky L, and Burman KD. "Discontinuing Antithyroid Drug Therapy before Ablation with Radioiodine in Graves Disease". *Ann Int Med*, 121:553-614, 1994.
180. Burman, KD. How serious are the risks of thyroid hormone over replacement? *Thyroid Today XVIII*, October-December, 1995.
181. Atwa MA, Lukes YD, Salata K, Abo-Hashem EM, El-Kannishy MH, Burman KD. The influence of triiodothyronine, thyroxine, thyrotropin and methimazole on thyroid cell MHC Class II antigen expression. *Clinical Immunology and Immunopathology*. 76: 209-213, 1995.
182. Kushner J and Burman KD. Can catabolism be reversed and survival enhanced by altering glucose, somatostatin, and glucagon levels in systemically ill patients? *Critical Care Medicine*. 23(1):1-2, January 1995.
183. Burman KD. Thyroid Cancer I. *Endocrinology and Metabolism Clinics of North America*, 24 (4), 1995.

184. Burman KD. How serious are the risks of thyroid hormone over-replacement? *Thyroid Today*, XVIII:(4), 1995.
185. Burch HB, Wartofsky L, Burman KD. Antithyroid drugs and radioiodine therapy. *Ann Intern Med* 122: 554-555, 1995.
186. Atwa MA, Smallridge RC, Burch HB, Gist ID, Lu R, Abo-Hashem EM, El-Kannishy MH, and Burman KD. Immunoglobulins from Graves' Patients Stimulate Phospholipase A₂ and C Systems in FRTL-5 and Human Thyroid Cells. *European J of Endocrinology*, 135: 322-327, 1996.
187. Solomon BL, Wartofsky L, Burman KD. Current Trends in the Management of Well Differentiated Papillary Thyroid Carcinoma, *Journal of Clinical Endocrinology & Metabolism*, 81:(1), 1996.
188. Burman, KD. Does T₃ mediate cold adaption? (Editorial) Submitted. January 20, 1996.
189. Burman KD. Is triiodothyronine administration beneficial in patients undergoing coronary artery bypass surgery? *JAMA*, 275: 723, 1996.
190. Burman KD, Ringel MD and Wartofsky L. Unusual Types of Thyroid Neoplasms. *Endocrin & Metabol Clinics of NA*, 25:49-68, 1996.
191. Burman KD. Does T₃ Mediate Cold Adaptation? Editorial, *Endocrin & Metabol*, 3: 1-5, 1996.
192. Tseng YL, Lahiri S, Nicholson D, Burman KD and Wartofsky L. Evidence of an association of endothelin-1 receptor expression to the active growth phase of the cell cycle and identification of endothelin-1 mRNA in FRTL5 cells. *Endocrin & Metabol*, 3:37-47, 1996.
193. Burman KD. How does thyroid hormone alter nutrient and energy metabolism? *Endocrine & Metabol (Editorial)*, 3:215-217, 1996.
194. Burch HB, Burman KD, Reed HL, Bucker L, Raber T and Ownbey JL. Fine Needle Aspiration of Thyroid Nodules. Determinants of insufficiency rate and malignancy yield at thyroidectomy. *Acta Cytologica*, 40:1176-83, 1996.
195. Smallridge RC, Tsokos GC, Burman KD, Porter L, Cranston T and Solomon BL. Soluble Interleukin-2 Receptor is a thyroid hormone dependent early response marker in the treatment of thyrotoxicosis. *Clinical and Diagnostic Laboratory Immunology* 4: 583-586, 1997.
196. Burman KD. Graves' Ophthalmopathy: What is the initial abnormality? *European J of Endocrinology*, 136: 583-585, 1997.
197. Burman KD. Thyroid Disease and Osteoporosis. *Hospital Practice*, 32: 71-86, 1997.
198. Burman KD. Immunoassays, Nonradionucleotide. *Encyclopedia of Human Biology*, 4:701-706, 1997.
199. Ringel MD, Taylor T, Barsouk A, Wall JR, Freter CE, Howard RS, Diehl L, Burman KD. Hodgkin's disease treated with neck radiation is associated with increased antibody dependent cellular cytotoxicity against human extra ocular muscle cells. *Thyroid* 7: 425-432, 1997.

200. Prendiville S, Burman KD, Wartofsky L, Ringel MD and Sessions RB. Evaluation and treatment of post thyroidectomy hypocalcemia. *The Endocrinologist* 8: 34-40, 1998.
201. Burman KD, Pandian R. Clinical utility of assays for TSH receptor antibodies. *The Endocrinologist* 8: 284, 1998.
202. Burch HB, Barnes S, Nagy EV, Sellitti D, Burman KD, Bahn RS, Lahiri S. Immunodetection of manganese superoxide dismutase in cultured human retro ocular fibroblasts using sera directed against the thyrotropin receptor. *J Endocrinol Invest.* 21:48-55, 1998.
203. Pacak K, Sweeney DC, Wartofsky L, Mark AS, Punja U, Azzam CJ, Burman KD. Solitary cerebellar metastasis from papillary thyroid carcinoma; a case report. *Thyroid* 8: 327-335, 1998.
204. Lu R, Wang P, Wartofsky L, Sutton BD, Zweier JL, Bahn RS, Garrity J, Burman KD. Oxygen free radicals in IL-1 beta induced glycosaminoglycan production by retro ocular fibroblasts from normal and patients with Graves' Ophthalmopathy. *Thyroid* . 9:297-303, 1999.
205. Wartofsky L, Burman KD, Ringel MD. Trading one "dangerous dogma" for another? *J Clin Endocrinol Metab.* 84:1759-60, 1999.
206. Ringel MD, Balducci-Silano P, Anderson JS, Spencer CA, Silverman J, Sparling YH, Francis GL, Burman KD, Wartofsky L, Ladenson PW, Levine MA, Tuttle RM. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. *J Clin Endocrinol Metab.* 84: 4037-4042, 1999.
207. Ringel MD, Burman KD, Shmookler BM. A Clinical aspects of miscellaneous and unusual cancers of the thyroid@ in *Thyroid Cancer: A comprehensive guide to clinical management* edited by Wartofsky L, Humana Press, New Jersey, 1999.
208. Burman KD, Wartofsky L. Iodine Effects on the Thyroid Gland: Biochemical and Clinical Aspects. In *Reviews in Endocrine and Metabolic Disorders*, Kluwer Academic Publishers, Volume 1, Issue 2, in press. Co-Editor, *Reviews in Endocrine and Metabolic Disorders*, Volume 1, Issues 2 and 3, *Thyroid Diseases*, Editorial comment in each issue.
209. Burman, KD, Graves' Disease and Thyroid hormone changes in the intensive care unit setting. Two chapters In *Principles and Practice of Endocrinology and Metabolism*, editor KL Becker, J.B. Lippincott Co, Philadelphia.
210. Burman KD. Thyroid disease and osteoporosis. *Hospital Practice* 32:71-86, 1997.
211. Burman KD, Becker RL, Cytryn A, Goodglick T, Graves' disease, Chapter 7, in *Atlas of Clinical Endocrinology*, Current Medicine, Philadelphia, 1999.
212. Burman KD, Hypothyroidism, Medscape. Com, Dec, 1999.
213. Prendiville S, Burman KD, Ringel MD, Shmookler BM, Deeb ZE, Wolfe K, Azumi N, Wartofsky L, Sessions RB. Tall cell variant: an aggressive form of papillary thyroid carcinoma. *Otolaryngology Head Neck*, Mar, 2000 122(3):352-7

214. Newkirk KA, Ringel, Jelinek JJ, Mark A, Wartofsky L, Deeb ZE, Beaudet L, Burman, KD. Ultrasound guided fine-needle aspiration and thyroid disease. *Otolaryngol. Head and Neck Surg.* 123:700-705, 2000.
215. Gardner R, Tuttle RM, Burman KD, Haddady S, Truman C, Wartofsky L, Sessions RB, Ringel MD. Prognostic importance of vascular invasion in papillary thyroid carcinoma. *Arch Otolaryngol Head Neck Surg.* 126: 309-312, 2000.
216. Ringel MD, Greenberg M, Chen X, Hayre N, Suzuki K, Priebat D, Saji M, Burman KD. Cytotoxic activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against poorly differentiated human thyroid carcinoma cells. *Thyroid.* 10:865-9, 2000.
217. Burman KD, Wartofsky L. Iodine Effects on the Thyroid Gland: Biochemical and Clinical Aspects. *Endocrine & Metabolic Disorders.* 1:19-25, 2000.
218. Fadel BM, Ellahham S, Ringel MD, Lindsay Jr., Joseph, Wartofsky L, Burman KD, Hyperthyroid Heart Disease, *Clin. Cardiol.* 23:402-408, 2000.
219. Wartofsky L, Ringel MD, Burman KD. Therapy of Graves' Ophthalmopathy. Chapter 19 pages 257-278. in *Graves' Disease: Pathogenesis and Treatment*, Kuwer Academic Publishers, Boston, 2000.
220. Kazlauskaitė R, Weintraub BD, Burman KD. Evaluation of thyroid function tests/ Chapter 48 Pages 2821-2829 in *Kelley's Textbook of Internal Medicine*, Fourth Edition, Edited by H. David Humes, Lippincott Williams and Wilkins, New York, 2000.
221. Thomas, J. Taylor, Susan S. Donlon, Allen E Bale, Robert C. Smallridge, Thomas B. Francis, Reed S. Christensen, and Kenneth D. Burman. Treatment of a Thyrotropinoma with OctreotideLAR in a Patient with Multiple Endocrine Neoplasia – 1. *Thyroid*, 10:1001-1007, 2000.
222. Newkirk KA, Ringel MD, Wartofsky L, Burman KD. The Role of Radioactive Iodine in Salivary Gland Dysfunction. *Ear, Nose, & Throat Journal.* 79(6):460-8, 2000.
223. Burman KD, Cooper DS. The Diagnostic Evaluation and Management of Hyperthyroidism due to Graves' Disease, Toxic Nodules and Toxic Multinodular Goiter. In *Medical Management of Thyroid Disease* (Chapter 2; pages 33-92), edited by Cooper DS, Marcel Dekker, Inc., New York, 2001.
224. Burman KD, Wartofsky L. Thyroid function in the intensive care unit setting. *Crit Care Clin.* 2001 Jan;17:43-57, 2001.
225. Burman KD. Graves' Disease in Women. Proper therapy depends on an accurate diagnosis. *Women's Health in Primary Care.* 2001 April(4):306-308.
226. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M. Overexpression and overactivation of Akt in thyroid carcinoma. *Cancer Res* 61: 6105-6111, 2001.

227. Stathatos N, Levetan C, Burman KD, Wartofsky L. The controversy of the treatment of critically ill patients with thyroid hormone. *Best Practice & Research Clinical Endocrinology & Metabolism*. 15:465-78, 2001.
228. Ringel MD, Hardy E, Bernet VJ, Burch HB, Schuppert F, Burman KD, Saji M. Rapid Communication: Metastin Receptor is Overexpressed in Papillary Thyroid Cancer and Signals through MAP Kinase in Thyroid Cancer Cells. *J Clin Endocrinol Metabol*. 2002; 87:2399-2402
229. Bernet VJ, Burman KD. Somatic mutations: Hot thyroid nodules, clonal adenoma, pgs. 239-249 in *Hormone Resistance and Hypersensitivity States*. Ed Chrousos G, Olefsky JM, Samols E. *Modern Endocrinology Series*, Lippincott Williams and Wilkins, Philadelphia, 2002.
230. Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, Burman KD, Burch HB, Ringel MD. Determination of Galectin-3 Messenger Ribonucleic Acid Overexpression in Papillary Thyroid Cancer by Quantitative Reverse Transcription-Polymerase Chain Reaction. *JCEM*, 87(10):4792-6, 2002
231. Ringel MD, Hardy E, Bernet VJ, Burch HB, Schuppert F, Burman KD, Saji M. Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. *Journal of Clinical Endocrinology & Metabolism*. 87:2399, 2002.
232. Shrier DK, Burman KD. Subclinical hyperthyroidism: controversies in management. *American Family Physician*. 65:431-8, 2002.
233. Oertel Y, Burman KD, Boyle L, Ringel MD, Wartofsky L, Shmookler B, Yeganeh F, Van Nostrand D. Integrating fine-needle aspiration into a daily practice involving thyroid disorders: The Washington Hospital Center Approach. *Diagnostic Cytopathology* 27:120-122, 2002.
234. Ousman Y, Burman KD. *Endocrine Function in Obesity*, Chapter 12. Endotext.com. www.endotext.org/obesity/obesity12/obesity12.htm, 2002
235. Premachandra BN, Radparvar A, Burman KD, Williams IK. Apparent Increase in Type I 5'Deiodinase Activity Induced by Antiepileptic Medication in Mentally Retarded Subjects. *Hormone Research* 58:273 -278, 2002.
236. Szucs-Farkas Z, Toth J, Balazs E, Galuska L, Burman KD, Karanyi Z, Leovey A, Nagy EV. Using morphologic parameters of extraocular muscles for diagnosis and follow-up of Graves' ophthalmopathy: diameters, areas, or volumes? *Am J Roentgenol*.179:1005-10, 2002.
237. Burman KD. Topics in Thyroid Disease: A 75-year-old woman with unexplained weight loss. *Medscape Diabetes & Endocrinology*. 2003; 5 (1). Available at: www.medscape.com/viewarticle/451749
238. C A Koch, F M Brouwers, K Rosenblatt, K D Burman, M M Davis, A O Vortmeyer, K Pacak. Adrenal ganglioneuroma in a patient presenting with severe hypertension and diarrhea. *Endocrine-Related Cancer*. 10:99-107, 2003.
239. R B Sessions, K D Burman. *Cancer of the Thyroid Gland. Head and Neck Cancer; A Multidisciplinary Approach; Second Edition*, 2003. Edited by Harrison, L, Sessions, R and Hong, Published by Lippincott, Williams and Wilkins. Chapter 29 pages 714-785.

240. Kwaku M, Burman KD, Becker KL, Mannan M. The EUROPA trial.[comment]. *Lancet*. 362:1935; 2003.
241. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. [Consensus Development Conference.] *JAMA*. 291(2):228-38, 2004.
242. Braga-Basaria M, Hardy E, Gottfried R, Burman KD, Saji M, Ringel MD. 17-Allylamino – 17Demethoxygeldanamycin Activity Against Thyroid Cancer Cell Lines Correlates With Heat Shock Protein 90 Levels. *JCEM*, 89:2982-8, 2004.
243. Hodak SP, Burman KD. The calcitonin conundrum--is it time for routine measurement of serum calcitonin in patients with thyroid nodules *Journal of Clinical Endocrinology & Metabolism*. 89(2):511-4, 2004 Feb.
244. Burman KD. A New Paradigm in the Treatment of Carcinoma: Specific Molecular Targeting. *Endocrinology*. 145(3):1027-30, 2004.
245. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD. Akt activation and localization correlate with tumor invasion and oncogene expression in thyroid cancer. *Journal of Medical Genetics*. 41(3):161-70, 2004.
246. Stathatos N, Burman KD. Diagnosis and Treatment of Hyperthyroidism. *Resident & Staff Physician*, Vol. 50, Number 9, 13 – 20, September 2004.
247. Hodak S, Burman KD, Burman E. Authors' Response: Should Serum Calcitonin Be Routinely Measured in Patients with Thyroid Nodules – Will the Law Answer Before Endocrinologists Do? *The Journal of Clinical Endocrinology and Metabolism*, 89:4769-4770, 2004.
248. Galuska L, Varga J, Szucs-Farkas Z, Nagy EV, Burman KD. Differences in SPET analysis of thyroid-associated orbitopathy. *European Journal of Nuclear Medicine & Molecular Imaging*. 31:793-5, 2004.
249. Stathatos N, Burman KD. Diagnosis and Treatment of Hyperthyroidism in Primary Care. *Resident & Staff Physician*. Vol.50, No.9, September 2004.
250. Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman KD, Jhiang S, Saji M, Ringel MD. Chronic Expression of RET/PTC 3 Enhances Basal and Insulin-Stimulated PI3 Kinase/AKT Signaling and Increases IRS-2 Expression in FRTL-5 Thyroid Cells. *Molecular Carcinogenesis*, 41:98-107, 2004.
251. Szucs-Farkas Z, Toth J, Kollar J, Galuska L, Burman KD, Boda J, Leovey A, Varga J, Ujhelyi B, Szabo J, Berta A, Nagy E. Volume Changes in Intra- and Extraorbital Compartment in Patients with Graves' Ophthalmopathy: Effect of Smoking. *Thyroid*, 15:146-151, 2005.
252. Burman KD. Diagnosis and Management of Hypothyroidism in Women. *Menopause Management*, Vol. 14, Number 3, May/June 2005

253. Jelinek JJ, Burman KD, Young RS, Mark AS. Magnetic Resonance Imaging and Computed Tomography Imaging of Thyroid Cancer. *Thyroid Cancer - A Comprehensive Guide to Clinical Management, Second Edition.* 38:359-366. Edited by L Wartofsky and D VanNostrand, Humana Press Inc, 2005
254. Burman KD. Special Presentations of Thyroid Cancer in Pregnancy, Renal Failure, Thyrotoxicosis, and Struma Ovarii. *Thyroid Cancer - A Comprehensive Guide to Clinical Management, Second Edition.* 42:387-392. Edited by L Wartofsky and D VanNostrand, Humana Press Inc, 2005
255. Hodak SP, Burman KD. Thyroid Carcinoma; Metastases to Bone. *Thyroid Cancer - A Comprehensive Guide to Clinical Management, Second Edition.* 53:497-508. Edited by L Wartofsky and D VanNostrand, Humana Press Inc, 2005
256. Burman KD, Wartofsky L. Hürthle Cell Carcinoma. *Thyroid Cancer - A Comprehensive Guide to Clinical Management, Second Edition.* 58:531-535. Edited by L Wartofsky and D VanNostrand, Humana Press Inc, 2005
257. Burman KD, Ringel MD, Shmookler BM. Miscellaneous and Unusual Types of Thyroid Cancer. *Thyroid Cancer - A Comprehensive Guide to Clinical Management, Second Edition.* 65:553-569. Edited by L Wartofsky and D VanNostrand, Humana Press Inc, 2005
258. Burman KD. Low Iodine Diets. *Thyroid Cancer - A Comprehensive Guide to Clinical Management, Second Edition.* 88:677-681. Edited by L Wartofsky and D VanNostrand, Humana Press Inc, 2005
259. Burningham A, Krishnan J, Davidson B, Ringel MD, Burman KD. Papillary and Follicular Variant of Papillary Carcinoma of the Thyroid: Initial Presentation and Response to Therapy. *Otolaryngology – Head and Neck Surgery.* 132(6):840-4,2005.
260. Saji M, Vasko V, Kada F, Albritton EH, Burman KD, Ringel MD. AKT Contains a Functional Leucine-rich Nuclear Export Sequence. *Biochemical and Biophysical Research Communications,* 332:167-73, 2005.
261. Burman KD. Diagnosis and Management of Hypothyroidism in Women. *Menopause Management,* 14, Number 3, May/June 2005
262. Juan Diez, Pedro Iglesias, Kenneth Burman. Spontaneous Normalization of Thyrotropin Concentrations in Patients with Subclinical Hypothyroidism. *The Journal of Clinical Endocrinology & Metabolism,* 90 :4124-4127, 2005.
263. Burman KD. Up to Date Chapters. Subacute Thyroiditis and Postpartum Thyroiditis. 2004 – present (online).
264. Stathatos N, Bordeau I, Espinosa A, Saji M, Vasko V, Burman KD, Stratakis C, Ringel MD. KiSS-1/GPR54 Metastasis Suppressor Pathway Increases MCIP-1 Expression and Chronically Inhibits Calcineurin Activity. *Journal of Clinical Endocrinology and Metabolism.* 90:5432-40, 2005.
265. Lu R, Burman KD, Jonklaas. Transient Graves' Hyperthyroidism During Pregnancy in a Patient with Hashimoto's Hypothyroidism. *Thyroid* 15: 725-29, 2005.

266. Burman KD. Should All Patients with a Thyroid Nodule Have Routine Serum Calcitonin Measurements? *Medscape Diabetes & Endocrinology* July 2005.
267. Holst J, Burman KD, Atkins F, Umans J, Jonklaas J. Radioiodine Therapy for Thyroid Cancer and Hyperthyroidism in Patients with End-Stage Renal Disease on Hemodialysis. *Thyroid*, 15:1321-31, 2005.
268. Burman KD. Hyperthyroidism. *Rakel and Bope: Conn's Current Therapy 2006, The Endocrine System*, p.806 – 811.
269. Burman KD. Micropapillary Thyroid Cancer: Should We Aspirate All Nodules Regardless of Size?. *Journal of Clinical Endocrinology and Metabolism*. 91:2043-46,2006.
270. Burman KD, McKinley-Grant L. Dermatologic Aspects of Thyroid Disease. *Clinics in Dermatology*, 24:247-55, 2006
271. Lu R, Burman KD. Pitfalls in Diagnosing and Treating Thyroid Disorders. *Women's Health in Primary Care*, 2006.
272. Wartofsky L, Van Nostrand D, Burman KD. Overt and 'Subclinical' Hypothyroidism in Women. *Obstetrical and Gynecological Survey*, 61, 8:535-542, 2006.
273. Hodak S, Huang C, Clarke D, Burman KD, Jonklaas J, Janicic J. Intravenous Methimazole in the Treatment of Refractory Hyperthyroidism. *Thyroid*. 16:691-695, 2006.
274. Lu R, Burman KD. Interpretation of Thyroid Function Tests. *Women's Health in Primary Care*, July-August 2006.
275. Kulkarni K, VanNostrand D, Atkins F, Aiken M, Burman KD, Wartofsky L. The Relative Frequency in Which and Empiric Dosage of Radioiodine would Potentially "Over-" or "Under-" Treat Patients Having Metastatic Well-Differentiated Thyroid Cancer. *Thyroid* 2006.
276. Nayak B, Burman KD. Thyrotoxicosis and Thyroid Storm. *Endocrinology and Metabolism Clinics of North America*. 35:663-86, 2006.
277. Kulkarni K. Van Nostrand D. Atkins F. Aiken M. Burman K. Wartofsky L. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. *Thyroid*. 16(10):1019-23, 2006 Oct.
278. Kwaku MP, Burman KD. Myxedema Coma. *Journal of Intensive Care Medicine*, 22:224-231, 2007
279. Monge C, DeMarco P, Burman KD, Wartofsky L. Autoimmune Thyroid Disease and Chronic Urticaria. *Clinical Endocrinology*, 67, 473-475, 2007.
280. Burman KD. Thyroid Function and Disease. Editor, *Endocrinology Clinics of North America*. Vol. 36, September 2007.
281. Devdhar M, Ousman YH, Burman KD. Hypothyroidism. *Endocrinology Clinics of North America*, 36:595-616, 2007.

282. Kundra P, Burman KD. Thyroid Cancer Molecular Signaling Pathways and Use of Targeted Therapy. *Endocrinology Clinics of North America*, 36:839-853, 2007.
283. Burman KD, Commentary on article by Ngo SY et al, entitled Cardiac abnormalities may be the dominant manifestations of thyroid storm in young men, *Clinical Thyroidology*, 19: 43, 2007.
284. Myers Adler S, Burman KD. Abnormalities in Thyroid Function Parameters and Subclinical Thyroid Disease in the Elderly: A Brief Review in *Hot Topics in Thyroidology*. (Online http://www.hotthyroidology.com/editorial_171.html).
285. Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Butler C, Atkins F, Burman K. Utility of PET/Neck MRI Digital Fusion Images in the Management of Recurrent or Persistent Thyroid Cancer. *Thyroid*. 18:103-11, 2008.
286. Burman KD. Editor, Thyroid Section. *A Case Based Guide to Clinical Endocrinology*, Editor Terry Davies, Humana Press, Inc.
287. Nadkarni PJ, Burman KD. Thyrotoxicosis. *Contemporary Endocrinology* Editor, G. Vandenberghe,
288. Gazdag A, Nagy EV, Burman KD, Paragh G, Jenai Z. Improved endothelial function and lipid profile compensate for impaired hemostatic and inflammatory status in iatrogenic chronic subclinical hyperthyroidism of thyroid cancer patients on LT4 therapy. Submitted, August 2008.
289. Nadkarni PJ. Sharma M. Zinsmeister B. Wartofsky L. Burman KD. Thyrotoxicosis-induced ventricular arrhythmias. *Thyroid*. 18:1111-4, 2008.
290. Burman KD. Does radioiodine therapy for Hyperthyroidism increase long-term morbidity? *Nature Clinical Practice Endocrinology & Metabolism*, Vol.4, No.5 252-253, May 2008.
291. Lando H, and Burman KB. Case Studies: Elevated CPK. *Endocrine Practice* Two cases of statin-induced myopathy caused by induced hypothyroidism. *Endocrine Practice*. 14:726-31, 2008
292. Burman KD. Commentary: discordant measurements of serum triiodothyronine (T4), thyroxine (T3) and thyroid-stimulating hormone (TSH). *Clinical Chemistry* 54: 1246, 2008.
293. Burman K. Hennessey J. McDermott M. Wartofsky L. Emerson C. The FDA revises requirements for levothyroxine products. *Thyroid*. 18:487-90, 2008.
294. Neff RL. Farrar WB. Kloos RT. Burman KD. Anaplastic thyroid cancer. [Review] [44 refs] *Endocrinology & Metabolism Clinics of North America*. 37(2):525-38, xi, 2008 Jun.
295. Ujhelyi B, Galuska L, Varga J, Szabados L, Balazs E, Bodor M, Erdei A, Leovey A, Mezosi E, Burman KD, Berta A, Nagy EV. Retrobulbar ^{99m}Tc-diethylenetriamine-pentaacetic-acid (DTPA) uptake predicts the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy. Retrobulbar ^{99m}Tc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy. *Thyroid*. 19(4):375-80, 2009.
296. Van Nostrand D, Aiken M, Atkins F, Moreau S, Garcia C, Acio E, Burman K, Wartofsky L. The Utility of Radioiodine Scans Prior to Iodine 131 Ablation in Patients with Well-Differentiated Thyroid Cancer. *Thyroid* 19:849-855, 2009.

297. Van Nostrand D, Atkins F, Moreau S, Aiken M, Kulkarni K, Wu JS, Burman K, Wartofsky L. Utility of the Radioiodine Whole-Body Retention at 48 Hours for Modifying Empiric Activity of 131-Iodine for the Treatment of Metastatic Well-Differentiated Thyroid Carcinoma Thyroid. October 2009: 1093-1098
298. Burman, K. Commentary - Thyroid-function test abnormalities are common in elderly people taking thyroid hormone-replacement medications. Thyroid Hormone, Vol. 21 April 2009.
299. Burman KD. Controversies surrounding pregnancy, maternal thyroid status, and fetal outcome. Thyroid. 19:323-6, 2009.
300. Karl M. Onumah BM. Cole J. Golding J. Burman KD. Wartofsky L. Hypocortisolemia in Graves hyperthyroidism. Endocrine Practice 15:220-4, 2009.
301. Loh JA. Wartofsky L. Jonklaas J. Burman KD. The magnitude of increased levothyroxine requirements in hypothyroid pregnant women depends upon the etiology of the hypothyroidism. Thyroid. 19(3):269-75, 2009.
302. Myers Adler S, Burman KD. Hypofunction: Chronic Thyroiditis. Clinical Management of Thyroid Disease, 2009.
303. Van Nostrand D, Atkins F, Bandaru V, Chennupati S, Moreau S, Burman K, Wartofsky L. Salivary Gland Protection with Sialagogues: A Case Study. Thyroid, 19:1005-8, 2009.
304. Klubo-Gwiezdzinska J, Wartofsky L. Thyrotropin blood levels, subclinical hypothyroidism, and the elderly patient. Archives Intern Med 2009; 169:1949-51.
305. Van Nostrand D, Atkins F, Bandaru VV, Chennupati SP, Moreau S, Burman K, Wartofsky L. Salivary gland protection from sialagogues: A case study. Thyroid 2009; 19:1005-1008.
306. Popoveniuc G, Sharma M, Devdhar M, Wexler J, Carroll N, Wartofsky L, Burman K. Graves' disease and Thymic Hyperplasia – The Relationship of Thymic Volume to Thyroid Function. Thyroid 20: 1, 2009.
307. Oertel YC, Burman KD. Variability in Reporting Fine Needle Aspirations of Thyroid. Thyroid 2010;20:109.
308. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L. Diagnostic and Therapeutic Use of Human Recombinant Thyrotropin (rhTSH)(Thyrogen®) in Well Differentiated Thyroid Cancer – Current Indications and Future Perspectives – A Review. Current Pharmaceutical Analysis, Vol 6, No.1, 2010.
309. Burman, K. Prophylactic Neck Dissection in Differentiated Thyroid Cancer, Concise Review. Clinical Thyroidology, February 2010.
310. Paes, J., Burman, K., Cohen, J., Franklyn, J., McHenry, C., Shoham, S., and Kloos, R. Acute Bacterial Suppurative Thyroiditis: A Clinical Review and Expert Opinion. Thyroid 20: 247, 2010.

311. Klubo-Gwiezdzinska J, Morowitz D, Van Nostrand D, Burman K, Vasko V, Soberman M, Wartofsky L. Metastases of Well-Differentiated Thyroid Cancer to the Gastrointestinal System. *Thyroid* 2010: 381-387.
312. Burman KD, Perioperative Management of Hyperthyroid Patients, *American College of Physicians, PIER Review, 2007-present.*
313. Klubo-Gwiezdzinska J, VanNostrand D, Burman K, Vasko V, Chia S, Deng T, Kulkarni K, Wartofsky L. Salivary Gland Malignancy and Radioiodine Therapy for Thyroid Cancer. *Thyroid* 20: 647, 2010
314. Gazdag A, Nagy EV, Burman KD, Paragh G, Jenei Z. Improved endothelial function and lipid profile compensate for impaired hemostatic and inflammatory status in iatrogenic chronic subclinical hyperthyroidism of thyroid cancer patients on L-T4 therapy. *Experimental & Clinical Endocrinology & Diabetes.* 118:381-7, 2010.
315. Over R, Mannan S, Nsouli-Maktabi H, Burman KD, Jonklaas J. Age and the Thyrotropin Response to Hyperthyroxinemia. *J Clin Endocrinol Metab* 95: 3675, 2010.
316. Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati S, Mete M, Burman K, Wartofsky L. 124 I Positron Emission Tomography Versus ¹³¹I Planar Imaging in the Identification of Residual Thyroid Tissue and/or Metastasis in Patients Who Have WellDifferentiated Thyroid Cancer. *Thyroid* 20:879, 2010.
317. Over R, Nsouli-Maktabi H, Burman KD, Jonklaas J. Age Modifies the Response to Recombinant Human Thyrotropin. *Thyroid* 20:1377, 2010.
318. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L. Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission? *Clinical Endocrinology* 74:111-117, 2010.
319. Tilluckdharry NV, Krishnamani R, DeNofrio D, Burman KD, Kim CS. Thyroid nodule and thyroid cancer management pre- and post-cardiac transplantation. *Journal of Heart and Lung Transplantation* 29: 831-7, 2010.
320. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L. Diagnostic and Therapeutic Use of Human Recombinant Thyrotropin (rhTSH)in Well-Differentiated Thyroid Cancer - Current Indications and Future Perspectives – A Review.” *CPA* 26:1-14, 2010.
321. Klubo-Gwiezdzinska J, Manes RP, Chia SH, Burman KD, Stathatos NA, Deeb ZE, Wartofsky L. Ectopic cervical thyroid carcinoma—Review of the literature with illustrative case series. *The Journal of Clinical Endocrinology & Metabolism.* 2011 Sep 1;96(9):2684-91.
322. Klubo-Gwiezdzinska J, Jensen K, Bauer A, Patel A, Costello J, Burman KD, Wartofsky L, Hardwick MJ, Vasko VV, The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress. *J Endocrinology* DOI:10.1530/JOE-12-0081; Vol. 214: 1-11, 2012; 214:207-216, 2012.
323. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L. Levothyroxine treatment in pregnancy: Indications, efficacy and therapeutic regimen. *J Thyroid Research*, Volume 2011 (2011), Article ID, doi:10.4061/2011/84391 (<http://www.hindawi.com/journals/jtr/2011/843591>).

324. Klubo-Gwiezdzinska J, Morowitz D, Van Nostrand D, Burman KD, Vasko V, Soberman M, Wartofsky L. Metastases of well-differentiated thyroid cancer to the gastrointestinal system. *Thyroid*. 20:381-7, 2010.
325. Krajewski DA, Burman KD. Thyroid Disorders in Pregnancy. *Endocrinology & Metabolism Clinics of North America*. Edited by Derek LeRoith, MD, PhD. *Endocrine Disorders During Pregnancy*. Dec 2011, Vol. 40, No. 4: 739-763.
326. Kulkarni K. Van Nostrand D. Mete M. Burman K. Wartofsky L. Detectability of foci of radioiodine uptake in the thyroid bed and neck comparing pinhole with parallel-hole collimators. *Nuclear Medicine Communications*. 32(5):369-74, 2011 May.
327. Klubo-Gwiezdzinska J, Manes RP, Burman KD, Stathatos NA, Deeb ZE, Wartofsky L. Clinical review: Ectopic cervical thyroid carcinoma- review of the literature with illustrative case series. *JCEM* 96(9):2684-91, 2011.
328. Klubo-Gwiezdzinska J, VanNostrand D, Atkins F, Burman K, Jonklaas J, Mete M, and Wartofsky L. Efficacy of Dosimetric Versus Empiric Prescribed Activity of ¹³¹I for Therapy of Differentiated Thyroid Cancer *JCEM* 96(10):3217-25, 2011 October.
329. Kundra P, Burman K. Thyroid Disorders and Disorders, *Medical Clinics of North America*. The Effect of Medications on Thyroid Function Tests. *Medical Clinics of North America*. 96: 283295, 2012.
330. Burman KD. Thyroid disorders and diseases. *Medical Clinics of North American* 96: xiii-xiv, 2012.(Editorial)
331. Burman K. Gestational Hyperthyroidism-a Need for Universal Screening? *Nature Reviews Endocrinology* 8:260-261, 2012.
332. Reyes-Castano J, Burman K. Thyrotoxic Crisis: Thyroid Storm. In press
333. Burman K, Commentary on “What is the Importance of Subclinical Hyperthyroidism?”. *Archives of Internal Medicine*. *Arch Int Med* 172: 809-810, 2012.
334. Brent G, Burman K. Management of Subclinical Hyperthyroidism. *Endocrine Essential: Endocrine Update for General Medicine*. Chapter 24:193-200.
335. VanNostrand D, Khorjekar G, O’Neil J, Moreau S, Atkins F, Kharazi P, Mete M, Chennupati S, Burman K, and Wartofsky L. Recombinant Human Thyroid-Stimulating Hormone Versus thyroid Hormone Withdrawal in the Identification of Metastasis in Differentiated Thyroid Cancer with ¹³¹I Planar Whole-Body Imaging and ¹²⁴I PET. *The Journal of Nuclear Medicine*, Vol. 53, No. 3, pg 359-362, March 2012.
336. Samson L. Czegeny I. Mezosi E. Erdei A. Bodor M. Cseke B. Burman KD. Nagy EV. Addition of chlorine during water purification reduces iodine content of drinking water and contributes to iodine deficiency. *Journal of Endocrinological Investigation*. 35(1):21-4, 2012
337. Klubo-Gwiezdzinska J. Burman KD. Van Nostrand D. Mete M. Jonklaas J. Wartofsky L. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of

- preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. *Thyroid*. 22(3):310-7, 2012.
338. Burman, KD. Thyroid disorders and diseases. Editorial, *Medical Clinic NA* 96:xiii-xiv, 2012.
339. Kundra P. Burman KD. The effect of medications on thyroid function tests. *Medical Clinics of North America*. 96: 283-295, 2012.
340. Burman, KD. Editorial: Treatment of Recurrent or Persistent Cervical Node Metastases in Differentiated Thyroid Cancer: Deceptively Simple Options. *J Clin Endocrinol Metab* 97: 2623-2625, 2012.
341. Klubo-Gwiedzinska J. Burman KD. Van Nostrand D. Mete M. Jonklaas J. Wartofsky L. Potential Use of Recombinant Human Thyrotropin in the Treatment of Distant Metastases in Patients with Differentiated Thyroid Cancer. *Endocrine Practice* 19:139-148, 2013.
342. Klubo-Gwiedzinska J, Jensen K, Costello J, Patel A, Hoperia V, Bauer A, Burman KD, Wartofsky L, Vasko V. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. *Endocr Relat Cancer*. 19:447-56, 2012.
343. Klubo-Gwiedzinska J. Jensen K. Bauer A. Patel A. Costello J Jr. Burman KD. Wartofsky L. Hardwick MJ. Vasko VV. The expression of translocator protein in human thyroid cancer and its role in the response of thyroid cancer cells to oxidative stress. *Journal of Endocrinology*. 214(2):207-16, 2012.
344. Klubo-Gwiedzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. *Endocrine Practice* 19: 139-148, 2013.
345. Popoveniuc G, Chandra T, Sud A, Sharma M, Blackman MR, Burman KD, Wartofsky L. A diagnostic scoring system for patients with myxedema coma. *Endocrine Practice* 20:808, 2014.
346. Van Nostrand D, Khorjekar GR, O'Neil J, Atkins FB, Kharazi P, Mete M, Chennupati SP, Burman KD, Wartofsky L. Recombinant human thyroid stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole body imaging and 124-I PET. *Journal Nuclear Medicine* 53L359-62, 2012.
347. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. *J Clin Endocrinol Metab* 97: 4549-58, 2012.
348. Smallridge RC. Ain KB. Asa SL. Bible KC. Brierley JD. Burman KD. Kebebew E. Lee NY. Nikiforov YE. Rosenthal MS. Shah MH. Shaha AR. Tuttle RM. American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. *Thyroid*. 22:1104-39, 2012.
349. Klubo-Gwiedzinska K, Costello J Jr, Patel A, Bauer A, Jensen K, Mete M, Burman KD, Wartofsky L, Vasko V. Treatment With Metformin Is Associated With Higher Remission Rate in Diabetic Patients With Thyroid Cancer *JCEM* 98: 3269-3279, 2013.
350. Eliades M, El-Maouche D, Choudhary C, Zinsmeister B, Burman KD. Takotsubo Cardiomyopathy Associated with Thyrotoxicosis: A Case Report and Review of the Literature. *Thyroid* 23:1-7, 2013

351. Estrada JM, Buckey TM, Burman KD, Soldin OP Thyrotropin Isoforms - Implications for Tsh Analysis and Clinical Practice. *Thyroid Thyrotropin Isoforms: Implications for Thyrotropin Analysis and Clinical Practice. Thyroid* 23: 1, 2014.
352. Jonklaas J, Burman KD, Bianco AC Treatment of hypothyroidism: possibilities on the horizon. *Thyroid* 23:ix-xi, 2013.
353. Burman KD, Commentary on: Discrepant Thyroid Function Test Results in a 44-Year-Old Man. *Clinical Chemistry* 59: 1706-7, 2013.
354. Kushchayeva Y, Jensen K, Recupero A, Costello J, Patel A, Klubo-Gwiedzinska J, Boyle L, Burman K, Vasko V. The HIV Protease Inhibitor Nelfinavir Downregulates RET Signaling and Induces Apoptosis in Medullary Thyroid Cancer Cells. *J Clin Endocrinol Metab.* 99:E734-E745, 2014.
355. Kushchayeva Y, Jensen K, Burman K, Vasko V. Repositioning therapy for thyroid cancer: new insights on established medications. *Endocr Relat Cancer* 6:21, 2014.
356. Kushchayeva YS, Kushchayev SV, Carroll NM, Felger EA, Links TP, Teytelboym OM, Bonichon F, Preul MC, Sonntag VK, Van Nostrand D, Burman KD, Boyle LM. Spinal metastases due to thyroid carcinoma: an analysis of 202 patients. *Thyroid.* 2014 Oct;24(10):1488-500.
357. Burman KD. Is Poorly Differentiated Thyroid Cancer Poorly Characterized? *J Clin Endocrinol Metab* 99: 1167, 2014.
358. Burch HB, Burman KD, Cooper DS, Hennessey JV. A 2013 Survey of Clinical Practice Patterns in the Management of Primary Hypothyroidism. *J Clin Endocrinol Metab* 99:2077-2085, 2014.
359. Jonklaas J, Sathasivam A, Wang H, Finigan D., Soldin O., Burman K., Soldin S. 3, 3⁻-Diiodothyronine Concentrations in Hospitalized or Thyroidectomized Patients: Results from a Pilot Study. *Endocrine Practice*, Epublished Feb, 2014
360. Jonklaas J, Sathasivam A, Wang H., Soldin O., Burman K., Soldin S. Thyroxine and Triiodothyronine: An Illustration of Measurement Discrepancies. Epublished. *Annals Clin Biochem*, 2014.
361. Jonklaas J, Burman KD, Latham K. Single Dose T3 Administration: Kinetics and Effects on Biochemical and Physiologic Parameters. Epublished, *Therapeutic Drug Monitoring*, 2014.
362. Burman KD, Jonklaas J. Thyroid Cancer and Other Thyroid Disorders. *Endocrinology & Metabolism Clinics of North America.* 43(2):xvii-xviii, 2014 Jun.
363. Goyal RM, Jonklaas J, Burman KD. Management of recurrent cervical papillary thyroid cancer. *Endocrinology & Metabolism Clinics of North America.* 43(2):565-72, 2014 Jun.
364. A.Bikas, K. Jensen, A. Patel, J. Costello, J. Klubo-Gwiedzinska, L. Boyle, L. Watofsky, K. Burman, V. Vasko. Glucose-Deprivation Increases Sensitivity to Metformin in Follicular and Papillary Thyroid Cancer Cells. *Endocr Relat Cancer.* 2015 Dec;22(6):919-32. doi: 10.1530/ERC-15-0402.

365. Atkins F, Van Nostrand D, Moreau S, Burman K, Wartofsky. Validation of a Simple Thyroid Cancer Dosimetry Model Based on the Fractional Whole-Body retention at 48 Hours PostAdministration of ^{131}I . *Thyroid* 25: 1347-1350, 2015.
366. Jonklaas J, Burman KD, Wang H, Latham KR. Single-dose T3 administration: Kinetics and Effects on Biochemical and Physiological Parameters. *Therapeutic Drug Monitoring* 37: 110-8, 2015.
367. A.Bikas, D. Van Nostrand, K. Jensen, S. Desale, M. Mete, L. Wartofsky, V. Vasko, K. Burman. Metformin Attenuates ^{131}I – Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer. *Thyroid*. 2016 Feb;26(2):280-6.
368. Burman KD, Wartofsky L. Thyroid Nodules. *N Engl J Med* 2015; 373:2347-2356.
369. A.Bikas, K. Priya, S. Desale, M. Mete, K. O’Keefe, B. Clark, L. Wray, C. Barrett, J. Jelinek, J. Wexler, L. Wartofsky, K. Burman. Phase II Clinical Trial of Sunitinib as Adjunctive Treatment in Patients with Advanced Differentiated Thyroid Cancer. *European Journal of Endocrinology* 174: 373-380, 2016.
370. A.Bikas, M. Schneider, S. Desale, M. Mete, K. Burman, L. Wartofsky, D. Van Nostrand. The Effects on Complete Blood Counts of Dosimetrically-Guided Prescribed Activity of I-131 in Patients with Differentiated Thyroid Cancer. *J Clin Endocrinol Metab* 101: 1762-1769, 2016.
371. Bartalena L, Burch HB, Burman Kahaly GJ. A 2013 European Survey of Clinical Practice Patterns in the Management of Graves’ disease. *Clinical Endocrinology* 84:115-120, 2016.
372. Burch HB, Burman KD, Cooper DS, Hennessey JV, Vietor NO. (2016). A 2015 survey of clinical practice patterns in the management of thyroid nodules. *Journal of Clinical Endocrinology & Metabolism*, 101, 2853-2862.
373. Bikas A, Vachhani S, Jensen K, Vasko V, Burman KD. Targeted therapies in thyroid cancer: an extensive review of the literature. *Expert Rev Clin Pharmacol*. 2016 Jul 15:1-15.
374. Singh I, Bikas A, Garcia CA, Desale S, Wartofsky L, Burman KD. ^{18}F -FDG-PET SUV as a prognostic marker of increasing size in thyroid cancer tumors. *Endocrine Practice*. 2017 Feb;23(2):182-189.
375. Burman KD, Braverman LE. What is the clinical role of oral liquid preparations in the treatment of patients with hypothyroidism? *Endocr Pract*. 2017 Feb;23(2):243-244.
376. Jensen K, Bikas A, Patel A, Kushchayeva Y, Costello J, McDaniel D, Burman K, Vasko V. Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells. *Endocr Relat Cancer*. 2017 Mar;24(3):147-156.
377. Niwattisaiwong S, Burman KD, Li-Ng M. Iodine deficiency: Clinical implications. *Cleveland Clinic Journal of Medicine*. 2017 Mar; 84(3):236-44.
378. Ordookhani A, Burman KD. Hemostasis in hypothyroidism and autoimmune thyroid disorders. *Int J Endocrinol* 2017 Apr;15(2).

379. Ordookhani A, Burman KD. Hemostasis in overt and subclinical hyperthyroidism. *Int J Endocrinol Metab*, 2017 Jul;15(3).
380. Sullivan SD, Downs E, Popoveniuc G, Zeymo A, Jonklaas J, Burman KD. Randomized trial comparing two algorithms for levothyroxine dose adjustment in pregnant women with primary hypothyroidism. *J Clin Endocrinol Metab* 102: 3499-3507, 2017.
381. Klubo-Gwiedzinska J, Costello J, Jensen K, Patel A, Tkavc R, Van Nostrand D, Burman K, Wartofsky L, Vasko V. Amifostine does not protect thyroid cancer cells in DNA damaging *in vitro* models. *Endocr Connect*. 2017 Oct 1;6(7):469-78.
382. Gomes-Lima CJ, Wu D, Kharazi PH, Khojekar GJ, Ringel MD, Vetter RJ, Bloom G, Burman KD, Wartofsky L, Van Nostrand D. Selected radiation aspects including transportation and lodging after outpatient 131-I therapy for differentiated thyroid cancer. *Thyroid* 27:1558-1565, 2017.
383. Gomes-Lima C, Burman KD. Delayed diagnosis of endocrinologic emergencies. *AHRQ WebM&M* [serial online]. November 2017. Available at <https://psnet.ahrq.gov/webmm/case/426>.
384. Jonklaas J, Murthy SR, Liu D, Klubo-Gwiedzinska J, Krishnan J, Burman KD, Boyle L, Carrol N, Felger E, Loh YP. Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes. *Future science OA*. 2017 Sep 22;4(1):FSO249.
385. Sidhu S, Parikh T, Burman KD. Endocrine Changes in Obesity. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc. Oct 2017; 2000-.
386. Younis IR, Ahmed MA, Burman KD, Soldin OP, Jonklaas JJ. Stable isotope pharmacokinetic studies provide insight into effects of age, sex, and weight on levothyroxine metabolism. *Thyroid*. 2018 Jan 1;28(1):41-9.
387. Ordookhani A, Motazed A, Burman KD. Thrombosis in thyroid cancer. *International Journal of Endocrinology and Metabolism*. 2018 Jan;16(1).
388. Ylli D, Burman KD, Van Nostrand D, Wartofsky L. Eliminating the Age Cutoff in Staging of Differentiated Thyroid Cancer: The Safest Road? *Journal of Clinical Endocrinology & Metabolism*. 2018 May 7;103(5):1813-7.
389. Wu D, Ylli D, Lima CJ, Lee W, Burman KD, Wartofsky L, Van Nostrand D. Use of 99m Tcsestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management. *Endocrine*. 2018 May 24:1-7.
390. Gomes-Lima C, Burman KD. Reverse T3 or perverse T3? Still puzzling after 40 years. *Cleveland Clinic Journal of Medicine*. 2018 Jun;85(6):450.
391. Gomes-Lima CJ and Burman KD. Hypothyroidism. In: Luster M, Duntas L, Wartofsky L, editors. *The Thyroid and Its Diseases: A Comprehensive Guide for the Clinician*. Springer 2018 Jun 28:235.

392. Gomes-Lima CJ, Nikiforov YE, Lee W, Burman KD. Synchronous Independent Papillary Thyroid Carcinomas in Struma Ovarii and the Thyroid Gland with Different RAS Mutations. *Journal of the Endocrine Society*. 2018 Jul 10;2(8):944-8. <https://doi.org/10.1210/js.2018-00132>
393. Luo H, Tobey A, Auh S, Cochran C, Zemska M, Reynolds J, Lima C, Burman K, Wartofsky L, Skarulis M, Kebebew E. The Effect of Lithium on the Progression Free and Overall Survival in Patients with Metastatic Differentiated Thyroid Cancer Undergoing Radioactive Iodine Therapy. *Clinical endocrinology*. 2018 Oct;89(4):481-8.
394. Bikas A, Wu D, Bethancourt E, Orquiza M, Bloom G, Burman KD, Wartofsky L, Van Nostrand D. Detection at public facilities of 131I in patients treated for differentiated thyroid cancer: the frequency, sites, management by security agents, and recommended physician documentation for patients. *Journal of Nuclear Medicine*. 2018 Oct 25;jnumed-118.
395. Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. *Molecular Cancer*. 2018 Dec;17(1):154.
396. Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Indeterminate Cytology: A Prospective Blinded Multicenter Study. *JAMA Oncology*. 2018 Nov 8.
397. Gomes-Lima CJ, Wu D, Rao SN, Pudukollu S, Hritani R, Zeymo A, Deeb H, Mete M, Aulisi EF, Van Nostrand D, Jonklaas J. Brain Metastases from Differentiated Thyroid Carcinoma: Prevalence, Current Therapies and Outcomes. *Journal of the Endocrine Society*. 2018 Nov 21;3(2):359-71.
398. Saini S, Maker AV, Burman KD, Prabhakar BS. Genetic aberrations and alterations in signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*. 2018 Dec 31.
399. Wu D, Khorjekar G, Kharazi P, Moreau S, Kulkarni K, Burman KD, Wartofsky L, Van Nostrand D. Poor patient compliance with instructions for continuous sialogogues after 131I therapy. *Oral diseases*. 2019 Jan;25(1):158-63.

Revised 03.14.2019